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“Learning is a treasure that will follow its owner everywhere”  
“When the winds of change blow, some people build walls and others build windmills” 
 
Chinese proverbs 
  
ABSTRACT 
Aims: The overall aim of this thesis was to investigate the association of inflammatory 
biomarkers with cardiovascular disease (CVD) with the final scope to identify potential novel 
predictors of incident cardiovascular events (CVE). The specific objectives were: to study the 
association between levels of IL8 and the genetic variants at the IL8 and IL8 receptor genes 
with the occurrence of myocardial infarction (MI) and to explore if these genetic variants 
regulate IL8 levels (Study 1); to identify novel genetic variants associated with IL8 levels 
(Study II); to study the association of IL8 levels with the risk of CVE (Study III) and, finally, 
to investigate the association between the levels of soluble IL6 receptors (sIL6R and sgp130) 
with the occurrence of MI (Study IV).       
Materials and Methods: Study I, II and IV were based on the Stockholm Heart 
Epidemiology Program (SHEEP), a population-based case-control study of incident MI 
performed between 1992 and 1994 at the ten emergency hospitals within the county of 
Stockholm. Controls were randomly selected from the study base, using density sampling and 
matching for age, sex and hospital catchment area. The analyses performed in this thesis were 
restricted to non-fatal cases (n=1213) and matched controls (n=1561), with available 
biomarkers data. Exposure information was available from questionnaires, anthropometric 
measurements, blood samples and medical records. Study III was based on a cohort of 60- 
year-old men and women from Stockholm (60YO), a population-based prospective study 
performed between 1997 and 1999 in Stockholm County.  A total of 4232 individuals (78%) 
agreed to be enrolled in the study. Participants were followed for an average of 14.5 years for 
the assessment of CVE and cardiovascular mortality. Up to December 31, 2012, n= 491 cases 
were recorded. A nested-case control was conducted based on the full enumerated cohort. 
Controls (n= 981) were randomly selected from the study base having the same sex as the 
case, being alive, and not been classified as a case at the date of the CVE (+/- 60 days).                                                                                                                    
Results and Conclusions: Circulating levels of IL8 were associated with a reduced 
occurrence of non-fatal MI in the SHEEP population aged 45-70 years (Study I), whereas no 
association was observed with the risk of CVE- defined as fatal and non-fatal MI, fatal and 
non-fatal stroke and hospitalization due to angina pectoris in the 60YO cohort (Study III).                                
Median levels of IL8 did not vary according to IL8 and IL8 receptor genetic variants (Study 
I).  A SNP rs12075 A/G, Asp42Gly, mapping at the Duffy antigen receptor for chemokines 
(DARC) gene on chromosome 1 was associated with circulating IL8 in serum, but not in 
plasma. Homozygous carriers of the G allele had lower levels of IL8 (Study II). These 
findings were replicated in independent populations.  SIL6R and sgp130 had opposing 
associations with MI. Sgp130 was an effect modifier of the association of sIL6R with MI and 
there was an indication of a possible interaction between high sIL6R and low sgp130 with the 
risk of MI (Study IV). 
Our results suggest that differences in baseline characteristics of a study population, genetic 
predisposition and genetic regulation of biomarkers should be taken into account when 
interpreting the results of associations of biomarkers with CVD risk.  In a broader sense, the 
role of molecular pathways should be evaluated in studies aimed at analysing the risk 
associated with complex outcomes rather than applying single biomarker approaches. 
 
  
   
  
LIST OF SCIENTIFIC PAPERS 
 
This thesis is based on the following original articles/manuscript, which will be referred to in 
the text by their Roman numerals 
I.  
I. Velásquez IM, Frumento P, Johansson K, Berglund A, de Faire U, 
Leander K, Gigante B. 
Association of interleukin 8 with myocardial infarction: results from the 
Stockholm Heart Epidemiology Program. 
Int J Cardiol. 2014 Mar 1;172(1):173-8 
 
 
I.  I. Moreno Velásquez I, Kumar J, Björkbacka H, Nilsson J, Silveira A, 
Leander K, Berglund A, Strawbridge RJ, Ärnlöv J, Melander O, 
Almgren P, Lind L, Hamsten A, de Faire U, Gigante B. 
Duffy antigen receptor genetic variant and the association with 
Interleukin 8 levels. 
Cytokine. 2015 Jan 31;72(2):178-184. 
 
 
III. Moreno Velásquez I, Leander K,  Berglund A, Gajulapuri  A, de Faire 
U, Gigante B. 
Association of serum Interleukin 8 levels with incident cardiovascular 
events. Results from the cohort of 60 years old men and women from 
Stockholm using a nested case-control design.                                                  
Submitted. 
 
 
IV. Moreno Velásquez I* , Golabkesh Z*, Källberg H, Leander K, de Faire 
U, Gigante B. 
Circulating levels of Interleukin 6 soluble receptor and its natural 
antagonist, sgp130, and the risk of myocardial infarction.  
Atherosclerosis. 2015Apr 14; 240(2):477-481.  
 
 
*Contributed equally 
 
 
V.  
VI.            
 
 
 
 
 
  
RELATED PUBLICATIONS 
 
 
V. Moreno Velásquez I, Ärnlöv J, Leander K, Lind L, Gigante B, Carlsson AC. 
Interleukin-8 is associated with increased total mortality in women but not in 
men-findings from a community-based cohort of elderly.                               
Ann Med. 2015  Feb;47(1):28-33 
 
VI. Gigante B, Strawbridge RJ*, Velásquez IM*, Golabkesh Z, Silveira A, Goel 
A, Baldassarre D, Veglia F, Tremoli E, Clarke R, Watkins H, Hamsten A, 
Humphries SE, de Faire U.                                                                                   
Analysis of the role of interleukin 6 receptor haplotypes in the regulation of 
circulating levels of inflammatory biomarkers and risk of coronary heart 
disease.                                                                                                                      
PLos One. 2015 Mar 17;10(3) 
 
*Contributed equally 
 
 
 
VII.   
  
CONTENTS 
1 Introduction ..................................................................................................................... 1 
2 Background ...................................................................................................................... 2 
2.1 Definitions ............................................................................................................. 2 
2.2 Burden of disease .................................................................................................. 2 
2.3 General overview of CHD .................................................................................... 3 
3 Biomarkers....................................................................................................................... 8 
3.1 Interleukin 8 ........................................................................................................... 9 
3.1.1 IL8 in atherosclerosis ................................................................................ 9 
3.1.2 IL8 isoforms ............................................................................................ 10 
3.1.3 Circulating levels of IL8 and risk of CVD ............................................. 11 
3.2 Genetic Epidemiology of CVD ........................................................................... 11 
3.2.1 IL8 genetic variants and risk of CVD ..................................................... 12 
3.3 Beyond IL8: the Interleukin 6 cytokine family .................................................. 14 
3.3.1 Soluble Interleukin 6 receptor ................................................................. 14 
3.3.2 Soluble glycoprotein 130 ........................................................................ 15 
4 Aims ............................................................................................................................... 16 
5 Methods ......................................................................................................................... 17 
5.1.1 The SHEEP study .................................................................................... 17 
5.1.2 Cohort of 60 years old Men and Women from Stockholm.................... 23 
5.1.3 Replication cohorts .................................................................................. 26 
5.2 Statistical analyses ............................................................................................... 31 
5.2.1 Study I...................................................................................................... 31 
5.2.2 Study II .................................................................................................... 32 
5.2.3 Study III ................................................................................................... 33 
5.2.4 Study IV ................................................................................................... 34 
5.2.5 Selection of potential confounding factors ............................................. 35 
6 Results ............................................................................................................................ 37 
6.1.1 Study I...................................................................................................... 37 
6.1.2 Study II .................................................................................................... 37 
6.1.3 Study III ................................................................................................... 38 
6.1.4 Study IV ................................................................................................... 38 
7 Discussion ...................................................................................................................... 40 
7.1.1 Circulating IL8 and cardiovascular events ............................................. 40 
7.1.2 Genetics variants of IL8 and risk of MI ................................................. 44 
7.1.3 Circulating sIL6R and sgp130 and risk of MI ........................................ 47 
8 Methodological considerations ..................................................................................... 50 
9 Conclusions and future perspective .............................................................................. 55 
10 Summary in Swedish ..................................................................................................... 57 
11 Acknowledgements ....................................................................................................... 58 
12 References ..................................................................................................................... 61 
 
  
  
LIST OF ABBREVIATIONS 
ACS Acute coronary syndrome 
AP Attributable proportion 
ASA Acetyl salicylic acid 
BMI Body mass index 
CABGs Coronary artery bypass graft surgery 
CHD Coronary heart disease 
CHF Chronic heart failure 
Chr Chromosome 
CI Confidence interval 
CoV Coefficient of variation 
CRP C reactive protein 
CV Cardiovascular 
CVD Cardiovascular disease 
DALYs Disability adjusted life years 
ECG Electrocardiogram 
ECs Endothelial cells 
ESS Endothelial shear stress 
GWAs Genome wide association studies 
HRT Hormone replacement therapy 
HUVEC Human umbilical vein endothelial cells 
IL6 Interleukin 6 
IL8 Interleukin 8 
IL8R Interleukin 8 receptors 
IQR Interquartile range 
IRR Incidence rate ratio 
LDL Low density-lipoprotein 
MAF Minor allele frequency 
MI Myocardial infarction 
OR Odds ratio 
PC Principal components 
PCI Percutaneous coronary intervention 
PMN  Polymorphonuclear 
S Synergy index 
SCD Sudden cardiac death 
SNP Single nucleotide polymorphism 
sgp130 Soluble glycoprotein 130 
sIL6R Soluble Interleukin 6 receptor 
STEMI ST segment elevation myocardial infarction 
WHO World Health Organization 
  
  
  
  
  
  
  
  
  
  
  1 
1 INTRODUCTION 
 
Cardiovascular (CV) disease (CVD) is a global public health concern. Despite advances in 
diagnosis and treatment, by 2020, CVD will become the leading cause of death and disability 
worldwide, with the numbers of fatalities expected to increase to more than 24 million by 
2030 (1). Modifiable (e.g., smoking, physical inactivity, hypertension, diabetes, hyper-
dyslipidaemias, obesity) and non-modifiable conditions (family history, age, and sex) 
constitute risk factors for CVD (2).  
Coronary heart disease (CHD), the most common manifestation of CVD,  accounted for 77.7 
million disability adjusted life years (DALYs) in the adult population in 2010, and the burden 
of DALYs was projected to increase by 35% from 2004 to 2030 (3, 4).  A pivotal study, the 
Framingham Heart cohort, first of its kind, studied multiple risk factors that determine a 
person´s risk for CHD (5, 6). Today, much of the decline in CVD burden is due to reduction 
in risk factors which this study contributed to identify (7).  
However, current algorithms that are commonly used, such as the Framingham risk score and 
lipid parameters fail to identify all individuals at risk of a CV event (CVE): one out of five 
patients who suffer from CHD lacks one or more of the four conventional risk factors, which 
include hyperlipidaemia, diabetes mellitus, smoking and hypertension (8). This suggests that 
the participation of other additional factors contribute to the occurrence of a CVE. Moreover, 
individuals with one or only a few modifiable risk factors are the least likely to be targeted 
for preventive therapies (9, 10).  
In terms of cost-effectiveness, identifying novel factors that target the segment of the 
population at risk of CVD whom are not identified by the commonly used algorithms may 
have substantial public health implications. Therefore, in recent years, identification of novel 
biomarkers able to predict CV risk above and beyond the known CV risk factors has been an 
emerging field in epidemiological studies (9). 
Inflammation plays a role in the development of CHD (11). Thus, this thesis is focused on the 
association between inflammatory biomarkers and occurrence of CVE. Three biomarkers 
Interleukin 8, soluble Interleukin 6 receptor and soluble glycoprotein 30 have been evaluated 
as exposure. 
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2 BACKGROUND 
2.1 DEFINITIONS 
CVD is a broad term which defines a group of disorders of the heart and blood vessels 
including CHD, cerebrovascular diseases, peripheral arterial disease, congenital heart disease, 
rheumatic heart disease, deep vein thrombosis and pulmonary embolisms (12). 
CHD refers to all the spectrum of clinical manifestation of atherosclerosis in the coronary 
arteries from stable angina to acute coronary syndromes (ACS) (i.e., unstable angina and 
myocardial infarction (MI)).  
In the present thesis, the following diseases were considered as outcomes: 
Non-fatal MI: (Study I, II and IV) and CVE: a combined endpoint of CHD and ischemic 
stroke, either fatal or non-fatal (Study III). 
2.2 BURDEN OF DISEASE 
Population ageing is driving the global epidemic of chronic diseases (3). Despite the decline 
in mortality rate attributable to CVD in Western Europe and North America nowadays (13, 
14), CVD is still the leading cause of death worldwide. Eighty percent of all CVD deaths 
occur disproportionately in low-and middle-income countries (15).  
 
Figure 1. Age standardized incidence of acute myocardial infarction per 100000 inhabitants 
20 years old and older according to sex and calendar year, 1998-2012. Åldersstandardiserad 
Socialstyrensen MI trends. Hjärtinfarkter 1988–2012.  
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In Sweden, during the period 1988-2000, the age standardized incidence of acute MI 
decreased overall (Figure 1). In the year 2001, the introduction of the novel diagnostic 
criteria for MI (see section 2.3.1.2) increased the age-standardized incidence, and by the year 
2004, the incidence fell to the same levels as before the introduction of the new criteria, and 
then decreased each year after that. The MI mortality rate and case fatality has decreased in 
both, men and women. On the other hand, a recent study has shown that the overall 
incidences of MI and ischemic stroke decreased over time among men, but were stable over 
time among women  in Sweden (16). 
 
2.3 GENERAL OVERVIEW OF CHD 
2.3.1.1 Pathophysiology of MI 
 MI occurs as a result of rupture or superficial erosion of an atherosclerotic plaque. This event 
triggers the development of an occlusive thrombus in the coronary artery causing deprivation 
of oxygen supply and acute ischemia in the tissue distal to the occluded artery.  
Within the last few decades, overflowing evidence has characterized atherosclerosis as a 
chronic, inflammatory, fibroproliferative process with immune components (17, 18). 
However, the complexity of this process and the mechanisms underlying inflammation are 
only partly understood. The process of atherogenesis is latent for years before it becomes 
clinically significant and yet, not all atherosclerotic plaques lead to a clinically overt disease 
(19).  
Although the entire vasculature is exposed to the atherogenic effects of the systemic risk 
factors, atherosclerotic lesions form at specific regions of the arterial tree, thus the local 
hemodynamic forces, e.g. low endothelial shear stress (EES), are implicated in atherogenesis 
(20).  
The chain of events that precede the rupture of the atherosclerotic plaque can be summarized 
as reported in Figure 2 (21).  
1. Vascular cells are exposed to excess low-density lipoprotein (LDL) causing 
endothelial activation/dysfunction and the internalization and deposition of lipids in 
sub-intimal space. 
2. Recruitment of inflammatory cells, (neutrophiles, monocytes), one of the crucial 
events in atherogenesis, is triggered.  
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3. Once resident in the artery wall, monocytes undergo structural and functional 
alterations via macrophage colony-stimulating factor, and differentiate into tissue 
macrophages. 
4. Herein, macrophages sustain an inflammatory reaction and increase the oxidative 
stress. With the uptake of oxidized LDL (oxLDL) into the atherosclerotic lesions they 
form foam cells.   
5. Smooth muscle cells (SMCs) from the tunica media -the middle layer of the artery 
wall- may emigrate into the subintimal space to participate in the atheroma formation 
or proliferate and produce collagen and elastin to form a fibrous cap that covers the 
plaque.  
 
 
 
 
 
 
 
6. The content of the plaque is then a collection of foam cells, some of which die with 
the consequent release of lipids that accumulate extracellularly. If the clearance of 
dead cells is inefficient, accumulation of cellular debris and extracellular lipids form a 
lipid rich pool known as the necrotic core of the plaque (22). 
7. The necrotic core expands and the fibrous cap covering the plaque can be broken 
down by matrix degrading metalloproteinases (MMPs) secreted by macrophages. As 
Smooth muscle cells 
Macrophage   Foam cell oxLDL 
Necrotic core 
Thrombus  
2 3 4,5,6 7, 8 9 1 
Figure 2. Initiation and progress of atherosclerosis in the arterial wall. Adapted from 
Rodriguez JA et al., 2007. Metalloproteases, Vascular Remodeling, and Atherothrombosis 
Syndromes (21).  Mo: monocytes 
 
 
 Mo 
LDL 
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a consequence, the plaque becomes thinner and erodes leading to the so called- 
unstable or vulnerable plaque. 
8.  The disruption of the cap leads to the burst of the plaque and exposes the necrotic 
core to clotting factors and platelets in the circulation.  
9. Thereafter, the interaction between exposed atherosclerotic plaque components, blood 
cells and coagulation factors leads eventually to platelet activation and aggregation.  
Thrombus is formed at the endothelial surface in the lumen of the arteries leading to a 
partial or total occlusion of the vessel, with consequent cell death of the myocardium 
distal to the occlusion of which ACS is the  clinical manifestation (23). 
 
2.3.1.2 Evolution of MI diagnostic criteria 
The definition of MI has evolved over time as more sensitive and specific biomarkers have 
been developed. By the end of 1970´s, the World Health Organization (WHO) consensus for 
the definition of MI was based on a combination of two of the following three characteristics: 
typical symptoms (e.g., chest discomfort), enzyme rise and a typical electrocardiogram 
(ECG) pattern involving the development of Q waves (24).  
Later on, the diagnostic criteria for MI was redefined by the European Society of Cardiology 
and the American College of Cardiology in 2000 (25). This first universal MI definition 
emphasized the use of myocardial tissue specific biomarkers (troponin) to reflect the 
myocardial necrosis that may occur without symptoms and in the absence of ECG changes.  
Any necrosis in the setting of myocardial ischaemia was labelled as MI. The implementation 
of these criteria, as shown in several epidemiological studies, leads to a significant rise in the 
rate of diagnosis of acute MI (26, 27), as outlined earlier (section 2.2). Shortly after, the 
Global Task Force, made up of the European Society of Cardiology,  American College of 
Cardiology, and the World Heart Federation, updated the 2000 consensus document (25).  By 
2007, these principles had been redefined by the Second Global Task Force, and accepted by 
the WHO, including an emphasis on clinical factors which might lead to a MI (28).  
Even more recently, in 2012, the universal definition was updated for the third time by the 
Global Task Force. The new MI definition, described in Table 1, is based on clinical 
symptoms, biomarkers, ECG changes, cardio-imaging and angiographic data. The novel 
criteria underscore the importance of imaging to detect very small amounts of myocardial 
injury or necrosis (29). It is likely that availability of upcoming novel biomarkers able to 
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detect brief periods of minor ischemia will lead to a further reclassification of unstable angina 
pectoris as MI (30). 
2.3.1.3 Treatment 
Timely treatment is recommended in order to avoid cardiac damage or mortality. Invasive 
procedures e.g., percutaneous coronary intervention (PCI) or coronary artery bypass grafting 
(CABGs) have been widely incorporated into clinical practice. The preferred method for 
reperfusion of  ST segment elevation MI (STEMI) is primary PCI and its indication is based 
on timing from symptom onset and the patient´s clinical status (31). In addition to lifestyle 
changes recommended for secondary prevention, drug therapy with angiotensin converting 
enzyme inhibitors, antiplatelet drugs, beta-blockers and statins has been shown to reduce 
complications post MI (32).  
 
Table 1. Definition and criteria for acute MI. 
Any of the following criteria meets the diagnosis for MI: 
1. Rise/or fall of cardiac biomarker (preferably cardiac troponin) with at least one of the following: 
*Symptoms of ischemia 
*New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch 
block (LBB) 
*Pathological Q waves in the ECG 
*Imaging evidence of new loss of viable myocardium or new regional Wall motion abnormality 
*Identification of an intracoronary thrombus by angiography or autopsy. 
2. Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic 
ECG changes or new LBBB, but death occurred before cardiac biomarkers were obtained, or before 
values would be increased. 
3. Percutaneous coronary intervention (PCI) related MI arbitrarily defined by elevation of troponin 
values >5 times the 99th percentile URL if the pre-procedure value is normal. If baseline are 
elevated but are stable or falling, an increase of >20 % is required.  
In addition, patients should have either (I) symptoms suggestive or (II) myocardial ischemia or (III) 
new ischemic ECG changes or angiographic findings consistent with procedural complication or 
(IV) imaging demonstration of new loss of viable myocardium or new regional Wall motion 
abnormality are required. 
4. Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the 
setting of myocardial ischemia and with a rise/or fall of cardiac biomarker values with at least one 
value about the 99th percentile URL. 
5. Coronary artery bypass grafting (CABG) related MI is arbitrarily defined by elevation of cardiac 
biomarker values (>10 x 99th percentile URL). In addition, (I) new pathological Q waves or new 
LBBB (II) angiographic documented new graft or new native coronary artery occlusion or (III) 
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality 
Source: White H, Thygesen K, Alpert JS, Jaffe A. Universal MI definition update for cardiovascular disease. Curr Cardiol 
Rep. 2014;16(6):492. 
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2.3.1.4 General overview-Ischemic stroke  
Ischemic strokes, another clinical manifestation of CVD, accounts for 87% of all strokes (33). 
A pro-inflammatory phenotype is a feature shared by CHD and ischemic stroke. In fact, 
several studies have shown that systemic inflammation profile predisposes people to ischemic 
cerebrovascular disease and is involved in the physiopathology of brain ischemia (34, 35).  
Atherosclerosis contributes to a large proportion of strokes. Findings from a necropsy study 
reported that, compared to patients with other neurological diseases, atherosclerotic plaques 
and signs of MI were present in the coronary arteries of 72.4%  and 40%, respectively, of 
patients with fatal stroke (36). Furthermore, some of the conventional CV risk factors such as 
sex, age, alcohol intake, HDL cholesterol, and physical inactivity confer similar prediction for 
risk of ischemic stroke (37). A strong association with the risk of  stroke is observed in the 
presence of atrial fibrillation, prevalent stroke and hypertension, the later considered as the 
main risk factor for both, haemorrhagic and ischemic stroke (38).  
In addition, sex differences with regards to the occurrence and aetiology of stroke have been 
described. Compared to men, stroke affects a bigger proportion of women due to higher 
longevity and onset of disease in the elderly (39). While cardioembolism is the main cause of 
stroke in women, large and small vessel disease is the main cause among men (40). Likewise, 
disability/quality of life post-stroke are poorer in women (39).  
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3 BIOMARKERS  
A biological marker (biomarker) is “any substance, structure or process that can be measured 
in biospecimens and may be associated with health-related outcomes” (41). From a practical 
standpoint, certain characteristics such as validity, reproducibility, cost-effectiveness, and 
safety make a novel molecule attractive as a biomarker candidate (42). It is also essential to 
evaluate not only that biomarkers are independent predictors of disease, but also to 
distinguish if they are causally related to mechanisms underlying the disease of interest. They 
are categorized as biomarkers of exposure, which are used in risk prediction, and biomarkers 
of disease, used in screening, diagnosing and monitoring the disease progression (43).  
In CVD, the clinical practice relies upon the use of diagnostic and prognostic biomarkers; 
however we still lack biomarkers of prediction. Up to date, a number of inflammatory 
biomarkers in relation to CVD have been studied and so far, these biomarkers have proven to 
be of limited value as supplementary strategies in CVD risk assessment (44). Furthermore, 
across different studies, novel biomarkers have only marginally improved the metrics of 
reclassification, discrimination and calibration to ameliorate risk prediction above and beyond 
the traditional risk factors (45, 46). For instance, the association between C-reactive protein 
(CRP), an inflammatory marker, with CVD has been perhaps among the most extensively 
explored associations in epidemiological cohorts. Although high CRP levels may indicate 
increased CVD risk (47, 48), the pathophysiological role of this marker in the atherosclerotic 
process has been questioned (49). Recent genetic data from Mendelian randomization studies 
failed to provide evidence for a causative role of CRP in CVD (50, 51).  
Therefore, further research in the field of novel inflammatory biomarkers and their clinical 
validation is essential to elucidate if they can provide a better prediction of future CVE and to 
increase our understanding of the mechanisms in atherosclerosis related pathways (52). 
Chemokines and cytokines, such as Interleukin 8 (IL8) and Interleukin 6 (IL6), have been 
detected in human atherosclerotic plaques and regulate mechanisms by which innate and 
adaptive immune cells control plaque inflammation (53, 54).  It is hoped that further insights 
into these molecular mechanisms will lead to novel therapeutic strategies to decrease the 
persistent residual risk of CVD in the general population.
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3.1 INTERLEUKIN 8 
IL8, a chemokine circulating in picomolar concentrations, has been implicated in a wide 
range of acute and chronic inflammatory pathologies. IL8 is synthetized by various 
immunologic and nonimmunologic cells and exerts pleiotropic effects (55).   
3.1.1 IL8 in atherosclerosis 
IL8 participates at different stages in the initiation and development of atherosclerosis:   
1. Atherogenesis:  
IL8 binds to its endothelial receptors IL8R (CXCR1 or CXCR2) and acts as a 
chemoattractant for monocytes and neutrophils into the vascular wall (56), a pivotal 
step in atherogenesis (Figure 2).  
 
2. Transition from  acute to chronic inflammation 
 
 IL8 is involved in the transition from acute to chronic inflammation (57). As shown in 
Figure 3, during the early phases of the inflammatory process, IL8 is released from 
endothelial cells (ECs) and neutrophils upon thrombin stimulation (58), among others, 
and promotes the synthesis of a monocyte chemoattractant protein 1 (MCP-1).  IL8 also 
promotes the shedding of the soluble Interleukin 6 receptor (sIL6R) from cells that 
express it (e.g., hepatocytes and leukocytes).  
The sIL6R then binds to the Interleukin 6 (IL6) forming a complex which binds to the 
membrane bound glycoprotein 130 (gp130) and the intracellular signalling begins. The 
soluble form of gp130 (sgp130) is circulating after shedding or proteolysis of the 
gp130. The sgp130 has the ability to inhibit the complex sIL6R-IL6. 
 
 
 
 
 
 
               Acute inflammation          Chronic inflammation 
            
Figure 3. IL8 in the transition from acute to chronic inflammation. Leu: leucocytes. 
Endothelial cells 
IL8 
IL6 
IL6R 
sIL6R 
Gp130 
sgp130 
Endothelial cells Endothelial cells 
Leu 
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3. Atherosclerotic plaque destabilization 
IL8 promotes an imbalance between metalloproteinases and metallopeptidases due to 
the diminution of the level of tissue inhibitors of metalloproteinases (TIMP-1) 
triggering local extracellular degradation in the plaque fibrous cap (59).  
 
4. IL8 in thrombogenesis 
IL8 has been shown to increase production and surface expression of tissue factor, an 
important inducer of blood coagulation in monocytes (60) providing a potential link 
between inflammation and thrombosis.  
 
5. Cardiac remodeling after MI 
IL8 promotes angiogenesis (61), inhibits apoptotic response and therefore enhances 
ECs survival (62). IL8 mobilizes progenitor ECs from the bone marrow, which 
promote neovascularization (63). In experimental models of ischemic injury, high 
circulating IL8 may be an adaptive response of the myocardium for repair and 
revascularization to maintain oxygen supply after hypoxia/ ischemic injury (64). 
 
3.1.2 IL8 isoforms 
During the 90´s, a more complex role for IL8 in the inflammatory process was recognized, 
yet not fully addressed. IL8 circulates in two major isoforms: a 72-aminoacid monocyte-
derived form ([Ser-IL8]72) and a 77-aminoacid ([Ala-IL8]77), mainly produced by ECs (65).  
These two isoforms might be produced under different stimuli, at different times during the 
development and mediate different effects  (66) . Whereas  the  [Ser-IL8]72 isoform has been 
shown to be  more potent in stimulating neutrophils in in vitro assays (67),   [Ala-IL8]77   may 
attenuate inflammatory events at the interface between the blood and the vessel wall and has 
been shown to exert a cardioprotective effect in animal models of ischemia and reperfusion 
(68).   
The previous studies have prompted the hypothesis that IL8 affects the inflammatory process 
in a time dependent fashion- as pro-inflammatory in the early stages and as less inflammatory 
at a later stage (69). The change in activity  is likely to be mediated by a switch between the 
two circulating isoforms (66). However, it has also been reported that the anti/pro 
inflammatory properties of IL8 are not only correlated to the different effects of the 
circulating isoforms, but also to extrinsic factors such as the directionality of local 
concentration gradients and the proteolytic activity in the tissue microenvironment (70). More 
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recently, antirombin III has been shown to inhibit the conversion of [Ala-IL8]77   isoform to 
shorter forms (71).  
3.1.3 Circulating levels of IL8 and risk of CVD 
Few observational studies have evaluated the association between IL8 and CVD. The first 
study to report an association was the EPIC-Norfolk, a prospective population-based study, 
where elevated concentrations of plasma IL8 were associated with an increased risk of future 
CHD (72). Shortly after, an analysis performed in the population-based MONICA/KORA 
Augsburg cohort reported an association between IL8 and incident CHD independently of the 
conventional CV risk factors (73). However this association is attenuated in their final model 
after adjustments for CRP and IL6.  
Other researchers have reported associations of IL8 with risk of CVD in populations with 
established CVD.  IL8 predicted secondary CVE after 7 years of follow-up independently of 
other cytokines and CRP in patients with CHD (74). CVE was defined as CV death, non-fatal 
MI, angina pectoris, repeated revascularization after PCI or CABGs, heart failure, non-fatal 
cerebrovascular events and arrhythmia. In a sub-study derived from the CORONA trial, 
elevated levels of IL8 were associated with adverse outcomes in a population with chronic 
heart failure (CHF) where the primary endpoint was the composite of CV mortality, non-fatal 
MI or non-fatal stroke (75). 
 
3.2 GENETIC EPIDEMIOLOGY OF CVD 
The individual susceptibility to CVD is determined by an interaction between genetic and 
environmental exposures. Variability of a particular phenotype may be a consequence of  
genetic variation in individuals exposed to the same environment, and likewise, of different 
environmental milieu in individuals with the same genotype (76). 
Genetic epidemiology has been helpful in defining the degree of the genetic contribution to 
CVD from a population perspective. Heritability of CV death ranges from 50-60% among 
males and 33-55% among females according to twin studies, particularly at younger ages (77, 
78). On the other hand, the presence of some conditions such as elevated BMI, seem to 
reduce the influence of genetic variants on CVD risk, thus indicating that genetic factors 
participate more actively in the pathogenesis when other conventional CV risk factors with a 
genetic and an environmental component are absent (79). 
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Genome wide association studies (GWAS) have allowed the identification of genes 
contributing to atherosclerotic CVD. Data obtained from the collaboration among several 
research groups have shown associations of single nucleotide polymorphisms (SNPs) with 
risk of CVD [(80, 81) among others].                                                                                                         
As represented in Figure 4, further interest has arisen in investigating if (1) genetic variants 
associated with the risk of CVD are also (2) associated with levels of circulating biomarkers, 
given that (3) circulating biomarkers under investigation are associated with the risk of CVD.  
As summarized by the gray line (4), this approach, the so-called Mendelian randomization, 
has been discussed as a way to assess causal effects of a biomarker with the risk of CVD. 
  
 
 
 
 
 
Figure 4. Mendelian Randomization approach 
In order for the Mendelian randomization to hold, some assumptions are needed, such as that 
the genetic variant cannot affect the outcome through pathways other than through the 
circulating biomarkers (82) and that the interpretation may hampered if the genetic variant 
has pleiotropic effects (83).  
 
3.2.1 IL8 genetic variants and risk of CVD 
The IL8 gene maps on the chromosome 4q13-q21, while the IL8R gene maps on chromosome 
2q34-q35. Few studies have explored the association of polymorphisms in the IL8 gene with 
risk of CVD. In a case-control study, Vogiatzi and colleagues evaluated the -251 A/T variant 
in the promoter and the 781 C/T intronic polymorphism of the IL8 gene in patients with 
CHD, where CHD was defined as angiographic evidence of at least one pericardial coronary 
artery with more than 70% stenosis (84). The control group were age matched subjects 
without evidence of CHD, but at least one CV risk factor for CHD. They reported no 
association of these polymorphisms with risk of CHD. However, they found that in the group 
1 
2 3 
4 
Genetic variants 
Circulating biomarkers CVD 
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with CHD, individuals with the minor allele (AA) at the -251 A/T SNP as well as the 
combined genotype AA251TT781 were associated with a reduced risk of ACS.   
An opposite finding was reported in a study of a Chinese Han population where the minor 
allele at the -251 A/T SNP was associated with a 30% increase risk of ACS in individuals 
with established CHD, defined as having a stenosis (≥50%) in at least one major coronary 
artery branch (85).  Yet, the replication population, recruited from the same region using the 
same criteria, showed an inverse association with the risk of ACS.  
The association of the gene coding IL8R (CXCR1 and CXCR2) with risk of CVD, to our 
knowledge, has not been reported.  
 
 
  
 14 
 
3.3 BEYOND IL8: THE INTERLEUKIN 6 CYTOKINE FAMILY 
Interleukin 6, a cytokine involved in a wide variety of pathologies, has inflammatory and 
anti-inflammatory properties. In the setting of CVD, IL6 participates in the oxidation of 
lipoproteins, recruitment and activation of pro-inflammatory cells as well as in the pro-
coagulant activities (60, 86). Several cohorts and case-control studies have described an 
association between circulating IL6 levels with increased risk of MI (87, 88), all-cause and 
CV mortality in the elderly (89), as well as with the progression of atherosclerosis in patients 
with vascular risk factors (90).                        
However, the association of other novel members of the IL6 family, sIL6R and sgp130, with 
risk of CVD has been less studied. 
3.3.1 Soluble Interleukin 6 receptor 
IL6 can bind to a membrane-bound receptor or to a soluble receptor, each one of them 
triggering signals with selective effects (91). When IL6 binds to the membrane bound IL6R, a 
pathway named classic signalling, the initial immune response and induction of acute phase 
proteins in hepatocyte is triggered. This signalling is limited since this receptor is only 
present in hepatocytes and in immunological cells (neutrophils, monocytes/macrophages and 
some lymphocytes) (92). 
When IL6 binds to the sIL6R, the complex IL6-sIL6R binds to gp130 expressed in all human 
cell surfaces and  initiates the so-called trans-signalling pathway, (93). In this way, the 
response to IL6 is expanded to other cells that do not express the IL6 membrane bound 
receptor. The sIL6R can be generated by alternative splicing of the IL6R mRNA and by 
shedding of the membrane bound receptor, which accounts for 90-99% of the circulating 
sIL6R (94). This pathway may be more crucial for the pro-inflammatory effects of IL6 (95).  
Recently, genetics consortia have provided evidence for a causal role of the IL6R related 
pathways in CHD. A genetic variant causing an Asp358Ala aminoacid change in the 
membrane-bound of the IL6R was shown to be associated with a  slightly increased risk for 
CHD (80) as well as with a reduced  risk for CHD (51, 96, 97). The minor allele was 
associated with decreased concentrations of fibrinogen, CRP and with increased levels of 
sIL6R. This mutation constitutes the major determinant of the circulating sIL6R (98)  and  
has been shown to reduce shedding of the IL6R up to fivefold (99). These findings suggest 
that, in the presence of circulating IL6, this-genetic-variant-incrementing-sIL6R favours the 
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trans-signalling pathway; and thus underscores the importance of sgp130 levels as 
responsible for the adequate control of IL6 trans-signalling.  
3.3.2 Soluble glycoprotein 130 
Sgp130 acts as an inhibitor of the IL6-sIL6R complex, and therefore prevents its binding of 
the complex to the gp130 receptor. IL6 binds to the sIL6R with an affinity of around 1nM 
whereas the complex of IL6 and IL6R binds to gp130 with a 100 times higher affinity (95). 
As a result, IL6 binds to sIL6R and the IL6/sIL6R complex will be immediately neutralized 
by sgp130. Thus IL6 in the circulation is buffered by the sIL6R and the complex IL6-sIL6R 
is buffered by sgp130 (100). 
Recently, an experimental study in mice has reported a significant decrease in the 
development and progression of atherosclerotic plaques with pharmacological inhibition of 
the IL6 trans-signalling using the fusion protein sgp130Fc (101). In fact, the first human 
phase I study with sgp130Fc is ongoing in chronic inflammatory diseases (100). 
 Elevations in sgp130 serum levels have been associated with all-cause and CV mortality, in 
elderly patients with CHF of ischemic aetiology (102).  As well, a descriptive, small hospital-
based pilot study reported higher serum levels of sIL6R in acute MI and CHD patients as 
compared to controls but no differences in the sgp130 serum levels in the three groups (103). 
  
 16 
 
 
4 AIMS  
The overarching aim of this thesis was to investigate the association of inflammatory 
biomarkers with risk of CVD with the final scope to identify potential novel predictors of 
incident CVE. 
The specific aims were as follows: 
1. To study the association between levels of IL8 and the genetic variants at the IL8 and 
IL8 receptor gene with the occurrence of MI. 
2. To identify novel genetic variants associated with levels of circulating IL8. 
3. To study the association of serum levels of IL8 with the risk of incident CVE. 
4. To investigate the association between the sIL6R and sgp130 with the occurrence of 
MI.  
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5 METHODS 
5.1.1 The SHEEP study 
Results derived from this thesis (study I, II and IV) are based upon data obtained from the 
Stockholm Heart Epidemiology Program (SHEEP), a population-based case-control study 
conducted in Stockholm County. The study base comprised all Swedish citizens resident in 
the Stockholm County from 1992-1994 who were 45 to 70 years of age and were free of 
previous clinically diagnosed MI.   
5.1.1.1 Cases 
Incident non-fatal MI cases in the study base were continuously identified at 10 emergency 
hospitals within the county of Stockholm. Diagnosis of MI was based on two of the following 
criteria (i) clinical history (ii) augmented specified  levels of the enzymes creatine kinase and 
lactate dehydrogenase and (iii) specified ECG changes (pathologic Q-wave in at least two 
ECG leads), according to the Swedish Association of  Cardiology in 1992/1994 (104). Male 
cases were identified during a two year period (1992-1993) whereas female cases during 
three years (1992-1994).  If cases survived at least 28 days post MI, they were classified as 
non-fatal; otherwise, they were considered fatal cases. A larger proportion (97%) of 
hospitalized MI cases were treated in internal medicine departments where one cardiologist 
and 2-4 nurses per hospital were responsible for identifying study participants. Identification 
of the rest of the cases treated in other departments (surgery, geriatrics, nephrology, 
neurology, pneumology) was done through the computerized hospital discharge register. 
During the period January-October 1992, the upper age limit was 65 years; from 1 November 
1992 and onwards it was 70 years. 
5.1.1.2 Controls 
Controls were randomly sampled from the study base and identified through the 
computerized register of the Stockholm County population, using density sampling and 
matching for sex, age (5-year interval) and hospital catchment area. This selection of controls 
was done within 2 days of the case occurrence.  Five control candidates were sampled at the 
same time, so that a potentially non-responding control could be substituted by a different 
candidate who belonged to the study base at the time of the case occurrence. Due to some late 
response for the initial control, both the initial and a substitute control were included 
sporadically.  Consequently, more controls than cases were recruited.  
 18 
A total of 5452 subjects were enrolled in the study (2246 cases and 3206 controls). Non-fatal 
cases had a participation proportion of 87% (n= 1643) while controls had a participation 
proportion of 73% (n= 2339).   
Using the Stockholm County National Patient Register, both, case and control candidates 
were investigated for previous MI (ICD9-codes 410 or 412 or corresponding codes in 
previous ICD revisions) since 1975. 
The results of the studies using the SHEEP material in this thesis are restricted to non-fatal 
cases, who  volunteered to give a blood sample and had no further MI before blood sampling 
(n=1213), and their sex, age and their hospital catchment area matched controls (n=1561).  
Fatal cases (n=603) were excluded as the subjects did not provide blood samples.  
Clinical investigations were performed on average three months after the onset of disease (to 
allow the patients to regain metabolic stability) including collection of overnight fasting 
samples (whole blood for DNA extraction, serum, EDTA and citrated plasma). The serum 
samples were separated within 1 hour and kept frozen at -70° C until analysed.  The DNA 
was stored at -80° C. 
5.1.1.3 Exposure information: 
Postal questionnaires were distributed to non-fatal cases and controls, where extensive 
information on a variety of potential CV risk factors was collected. Unless the subject 
declined to participate, up to four reminders could be given if necessary. In addition, a 
complementary telephone interview was carried out to complete missing information.  
Participants were invited for health examinations that took place at the outpatient clinics of 
the 10 emergency hospitals. Controls undertook examination as close as possible to the date 
of the cases to avoid biases due to seasonal variation with regards to blood parameters. 
Anthropometric measurements such as BMI; (Kg/m
2
), systolic and diastolic blood pressure 
(SBP and DBP; mmHg) were assessed. Biochemical analyses were done using  
radioimmunoassay (RIA) kits [insulin (µU/L)], enzyme-linked immunosorbent assays 
(ELISA) [von Willenbrand factor, IL6], enzymatic colometric methods [total cholesterol 
(mmol/L), triglycerides, HDL cholesterol], immunochemical techniques [ApoA1 and ApoB1 
(g/L)], RIA techniques [insulin growing factor binding protein 1 (IGFBP1; mg/L)], fibrin 
polymerization test according to method described by Vermylen et al. (105) [fibrinogen 
(g/L)], spectrolyze PAI-kit [plasminogen activator inhibitor (PAI-1; mg/L)], high sensitive 
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immunoephelometric assay [CRP (mg/L)], serum glucose, blood lipids, Quantikine HS 
human TNF-α [tumour necrosis factor-α (TNF- α; ng/L)]. 
5.1.1.4 Ethics 
The SHEEP study was carried out in accordance with the Helsinki Declaration and was 
approved in 1991 by the Regional Ethical Review Board at Karolinska Institutet. Participants 
gave their oral informed consent since at the time of enrolment, no written informed consent 
was currently in use. 
5.1.1.5 Serum measurements 
5.1.1.5.1 IL8 
After thawing, 25 µL of the 1847 available serum samples (1133 controls and 714 cases) 
were measured for IL6 and IL8 concentrations using an electrochemiluminescence 
immunoassay plates from Meso Scale Discovery´s Multi-Array ® (MSD). Two sets of 
batches were analysed in 96 Well 4-Spot using MSD® 6000 instrument (n=1128 samples) 
and MSD SI2400® instrument (n=719 samples), following the manufacturer´s assay and 
analysis protocols. To anchor between the two batches, new and old calibrators were run on 
the same plate and at the same time. The limit of detection for each plate was determined 
based on the linearity of the standard curve following the manufacturer´s instructions. MSD 
appears to have a better sensitivity at lower concentrations for IL8, as compared to other 
analytical platforms (106).  
Duplicates (intra-intervariability) were measured in approximately 40 % of the samples and 
results were recorded as the average.  Samples with coefficient of variation (CoV) higher than 
25 (n=37) were excluded from the analyses. The intra-and interassay CoV were (%) 7.9 and 
8.0 respectively.  
 According to the number of times being thawed, samples were recorded as never been 
defrosted (n=1723), defrosted once (n=121) and defrosted twice (n=3). In order to determine 
if frequency of thawing influenced levels of IL8, n= 104 samples were measured repetitively 
to compare IL8 levels between samples that were never thawed and samples defrosted twice. 
Reproducibility was evaluated using the Spearman correlation coefficient. Correlation 
between the two measurements was 0.61. 
As added measurements of accuracy, levels of IL6 in serum were correlated to the IL6 levels 
measured earlier in the SHEEP by enzyme-linked immunosorbent assays (ELISA) (87). The 
two methods replicated fairly well. 
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5.1.1.5.2 sIL6R 
Serum concentrations of sIL6R were measured using the MesoScale Discovery (MSD) 
Human Cytokine Assay (Gaithersburg, MD, USA), in available serum samples, following the 
manufacturer’s assay protocol. In total, 1785 serum from study participants (682 cases and 
1103 controls) were measured. Samples were diluted 1:75 and concentrations were derived 
from the standard curve and are expressed in nanograms per milliliter (ng/mL). The minimum 
detectable level for sIL6R was 0.1 pg/mL.  
To calculate the intra variability of the assay, n= 267 samples for the sIL-6R were run in 
duplicate. In order to assess the inter assay variability n= 67 samples of the sIL-6R were run 
in independent experiments. The intra-and interassay CoV were 6.1 % and 3.8% respectively. 
5.1.1.5.3 sgp130 
Due to absence and/or scarcity of serum, a total of 1726 serum samples (664 cases and 1062 
controls) were measured in serum for concentrations of sgp130. We used an assay from R&D 
systems®, Quantikine® ELISA according to the protocol instructions. Samples required a 
100-fold dilution. To calculate the intra and intervariablity, n=25 samples were duplicated 
intra-plate, whereas n=37 samples were duplicated in independent experiments. Serum 
concentrations were derived from the standard curve and are expressed in ng/mL. Intra and 
intervariability of the plates were 1.8 and 12.1 % respectively. The minimum detectable 
amount of sgp130 was 0.08 ng/mL. 
5.1.1.6 Genotyping: 
One tag SNP at the IL8 (rs2227306C/T) which lies in the first intron of the gene and three tag 
SNPs in the IL8 receptors gene (rs6723449T/C, rs1008563C/T, rs4674258C/T) were 
genotyped by  MALDI-TOF (Matrix Adsorbed Laser Desorption-Ionisation-Time Of Flight) 
on Massarray analyser platform, after their identification using HapMap database. The 
numbers of subjects with genotype available were: IL8 SNP (1102 cases and 1434 controls), 
IL8 receptor rs6723449 (1154 cases and 1501 controls), IL8 receptor rs1008563 (1134 cases 
and 1465 controls), IL8 receptor rs4674258 (1143 cases and 1477 controls). 
 In addition, we have genotyped the promoter variant rs4073A/T, in position -251 in the IL8 
gene. This SNP was genotyped with a custom made assay purchased from Applied 
Biosystem (ABI) and amplified with the TaqMan Universal PCR protocol. Unfortunately, a 
fraction of the samples genotypes were missing as a result of failures in the DNA reading.  In 
total, n= 867 cases and n= 1035 controls were genotyped for rs4073.  
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5.1.1.7 Illumina iSelect CardioMetabo200kb  
Genomic DNA from the SHEEP study participants was genotyped using the Illumina iSelect 
CardioMetabo200kb (CardioMetabochip), a custom- made genotyping array that captures 
DNA variation at regions identified by meta-analyses of GWAS for diseases and traits 
relevant to metabolic and atherosclerotic/cardiovascular diseases. The array contained 
approximately 200,000 variants mapping at genomic region of potential relevance for these 
traits, identified by chromosomal location and/or SNP identification number (107).   
More detailed information on number of participants and selection criteria for Studies I-II and 
IV is presented in Figure 5.  
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Figure 5. Flowchart of the recruitment of participants in the SHEEP study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
reinfarction 
 
603 fatal cases 
2246     
CASES 
1643 NON FATAL MI 
(1105 men ,583 women) 
 
1381 replied only to questionnaire 
 
1267 underwent physical  
examination 
867 fatal cases 
3206 
CONTROLS 
2339 controls           
(1542 men, 797 
women) 
1697 replied only to questionnaire  
 
1563 underwent physical  
examination 
Genotyping: 
IL8 gene: 1102 rs2227306, 867 rs4073 
IL8R gene: 1154 rs6723449, 1134  rs1008563, 1143 
rs4674258 
                          Serum levels: 
714 IL8 (465 men, 249 women) 
682 sIL6R (444 men, 238 women) 
664 sgp130 (430 men, 234 women) 
 
1213 MI CASES 
1561 CONTROLS 
                           Serum levels: 
1133 IL8   (724 men, 409 women)                                              
1103 sIL6R (708 men, 395 women)                                        
1062 sgp130 (682 men, 380 women) 
Plasma levels:                                                               
703 IL8   (448 men, 255 women) 
Genotyping: 
IL8 gene: 1434 rs2227306, 1035 rs4073 
IL8R gene: 1501 rs6723449, 1465 rs1008563, 1477 
rs4674258 
 
2 MI pre-
physical 
examination 
  23 
5.1.2 Cohort of 60 years old Men and Women from Stockholm  
Results from Study III, were derived from the cohort of 60 years old Men and Women 
(60YO). The study base comprises men and women born between 1 July 1937 and 30 June 
1938 who were living in the Stockholm County between August1997 to March 1999.  
Every third man (n=2779) and women (n=2681) who turned 60 during the time period of 
recruitment were randomly selected from the Total Population Register in Sweden and 
invited to participate in a health screening for CVD. An invitation letter was sent by mail to 
eligible subjects informing them about the study. In this letter, it was asked kindly to contact 
a booking centre to inform whether he or she would like to participate or not. The nurses 
working at the booking centre documented each reply. A reminder was sent to those who did 
not reply to the first letter. 
 In total 5460 subjects, 2779 men and 2681 women, were invited, out of which 4232 
individuals participated; 2039 men (73%) and 2193 women (82%). The overall participation 
proportion was 78%. 
Yearly, the cohort is matched with the Swedish National Inpatient Register and the Cause of 
Death register in Sweden. Through linkage with the national registers, 491first time (incident) 
ischemic CVE were recorded up to December 31st 2012. The composite endpoint was 
defined according to the International Classification of Diseases 10
th
 Revision codes as fatal 
and non-fatal MI (I21, I25), fatal and non-fatal ischemic stroke (I63-I66), and hospitalization 
due to angina pectoris including PCI and CABGs procedures (I20, Z95.5 and Z95.1).  
Individuals with previous CVE (angina, stroke and MI) at baseline (n=369) and those who 
did not fill in the questionnaire (n=122) were excluded, leaving a total number of 3741 study 
participants (1990 women and 1751 men). Exclusion was assessed through 1) the Swedish 
National Inpatient Register and by 2) having reported in the questionnaire a previous MI, 
stroke, heart failure and/or angina /claudication.  
The study has been approved by the Regional Ethical Review Board at Karolinska Institutet, 
Stockholm, Sweden. All study participants gave their oral consent to be enrolled in the study, 
since written informed consent was not in current use at the time this study was conducted.  
5.1.2.1 A nested case- control design 
For study III, a nested case-control was designed. For each incident CVD case, two controls 
were randomly selected from the cohort, with the exception of 1 male participant where only 
1 control could be selected.  Selection of controls was done randomly from the study base 
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continuously over time (density sampling) and matched for sex and time at risk (those 
controls who were not classified as a case +/- 60 days at the date of the event) and who were 
still alive. 
More detailed information about number of participants and selection criteria for Study III is 
shown in Figure 6. 
5.1.2.2 Exposure information 
A comprehensive questionnaire regarding a wide range of exposures was distributed via mail 
and filled in by the study participants. If needed, a study nurse assisted with filling in the 
questionnaire. All participants underwent a thorough physical examination including 
anthropometrical tests and collection of ECG. Venous blood samples, including serum and 
plasma, were drawn from an antecubital vein after overnight fasting 24:00 the night before 
and stored at biobanks (-80 C).  
Blood pressure (systolic/diastolic) was measured twice after 5 minutes of rest and the mean 
value was calculated. BMI was computed from height and weight measurements and 
expresses in Kg/m
2
. Cholesterol and triglyceride levels in serum were analysed using 
enzymatic methods (Bayer Diagnostics, Tarrytown, NY, USA). Serum glucose was measured 
with an enzymatic colorimetric test (Bayer Diagnostics) (108).   
5.1.2.2.1 IL8 measurements 
Serum samples were retrieved from frozen storage, thawed, and IL8 levels were measured 
using electrochemiluminescence immunoassay multiplex plates produced from Meso Scale 
Discovery´s Multi-Array ® (MSD).  Serum concentrations were derived from the standard 
curve and expressed as picograms per millilitre (pg/mL). Together with IL8, other cytokines 
such as IL6, IL1 β and TNF-α were measured. Samples were analysed in a random order and 
blinded with regards to case-control status in order to avoid systematic bias. 
To calculate the intra and inter assay variability, n= 68 samples were run in duplicate and 
n=32 samples were run in independent experiments respectively. Intra and intervariability of 
the plates were 9.9% and 9.7%, respectively. 
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Figure 6. Flowchart of the recruitment of participants in the Cohort of 60 years old Men and 
Women from Stockholm.  
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5.1.3 Replication cohorts 
In Study II, the genetic associations observed in the SHEEP material required replication in 
independent studies. Therefore, the studies initially contacted were those where we could 
replicate our findings in silico, i.e., IL8 measurements were available and the same genetic 
variants had been genotyped.                                                                            
Our results were replicated in three independent populations derived from: 
5.1.3.1 The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) 
cohort:   
The cohort was established to investigate the predictive power of different measurements of 
endothelial function and arterial compliance in the elderly (109) . The study base comprised 
all subjects aged 70 years living in the community of Uppsala, Sweden from 2001-2004.  
Eligible subjects were chosen from the register of community living and were invited to 
participate in the study in a randomized order. Of the 2025 subjects invited, 1016 subjects 
agreed to be enrolled in the study (participation proportion of 50.1%). Participants were asked 
to answer a large questionnaire concerning their medical history, lifestyle factors and 
medication. Anthropometrical measurements, blood pressure and blood sampling was also 
undertaken at baseline. Sampling were drawn after an overnight fast and stored at -70 ° C 
until analysis. 
 The study was approved by the Ethics Committee of the University of Uppsala and the 
participants gave informed consent.   
5.1.3.1.1 IL8 measurements 
IL8 was measured on serum using Evidence array biochip analyser (Randox Laboratories 
Ltd, Crumlin, UK) (110). The functional sensitivity for IL8 was 1.5 pg/mL. From the 1016 
study participants, 13 individuals were excluded due to missing values on IL8, leaving 1003 
study participants. For our analysis, IL8 values were log transformed, and values =0 were 
excluded from the analysis, therefore n= 931 participants were included.  
Participants of the PIVUS study were genotyped using the CardioMetabochip. 
5.1.3.2 The Stockholm Coronary Artery Risk Factor (SCARF) study 
The SCARF study is a MI case-control study from the northern part of Stockholm designed 
to investigate novel biochemical and molecular genetic risk markers for CAD. From January 
1996 to December 2000, all individuals aged <60 years who were admitted for acute MI to 
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the coronary care units of the three hospitals (Danderyd, Karolinska and Norrtälje Hospital) 
in the northern part of Stockholm were considered for inclusion in the study (n=755). 
Exclusion criteria were those with previous MI (n=102), diabetes mellitus type 1 (n=23), 
renal insufficiency (n=9), any chronic inflammatory disease (n=13), drug addiction (n=10), 
psychiatric disease (n=3) or unwillingness to participate in the study (n=19). In addition 143 
participants were excluded due to psychosocial reasons, leaving a total number of 433 
participants. Out of those, individuals were excluded due to program incompleteness (n=51), 
withdrawn consent (n=19), comorbidities (n=12) or protocol violation (n=7), and deaths 
(n=3). This resulted in 387 first time MI cases. One control was randomly recruited from the 
general population via the Total Population Register matched on sex, age and residential area. 
About 3 months after the onset of MI, study participants were interviewed regarding medical 
history and lifestyle factors. Collection of whole blood for DNA extraction and plasma were 
collected under fasting conditions (111).  
The study was approved by the Ethics Committee of the Karolinska University Hospital and 
the participants gave informed consent. 
5.1.3.2.1 IL8 measurements:  
Fasting plasma concentrations of IL8 were determined using  Evidence® array biochip 
analyser (Randox laboratories ltd., Crumlin, UK) (110). IL8 was measured in n= 361 cases 
and n= 374 controls. In order to avoid the potential influence of the case status on IL8 levels, 
only controls with available IL8 measurements (log transformed) and with genotype were 
considered for analysis (n=350). 
Participants of the SCARF study were genotyped using the Cardiometabochip. 
5.1.3.3 The Malmö Diet and Cancer study-Cardiovascular cohort (MDC-CC) 
The Malmö Diet and Cancer study is a prospective population-based cohort consisting of 
30,447 individuals. Eligible participants comprised all men, age 46-73 years and women, age 
45-73 years, resident in Malmö from 1991 to 1996. Participants were invited to fill out a 
questionnaire as well as to undergo physical examination with blood sampling.  
Furthermore, a total of 6103 men and women were randomly invited to participate in the 
cardiovascular arm of the population- based MDC cohort, the MDC-CC, which is a sub-study 
of the epidemiology of CVD (112).  After 15 years, during 2007-2012, re-examination and 
blood sampling were performed in a subset of individuals (n=3300) that agreed to do so.  All 
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participants provided written informed consent and the study was approved by the Regional 
Ethical Review Board in Lund, Sweden.  
5.1.3.3.1 IL8 measurements 
Circulating levels of IL8 were measured at baseline in heparin plasma by an 
electrochemiluminescence immunoassay (Human Ultra-Sensitive Kit) using a SECTOR 
Imager 6000 instrument (MesoScale Discovery, Gaithersburg, MD, USA). Levels of IL8 in 
plasma were measured in close to 700 individuals (n=696) randomly selected from the 
cardiovascular arm of the MDC cohort. In addition, close to 800 individuals (n=797) with 
metabolic syndrome according to the updated NCEP III definition, were selected for IL8 
measurements. 
We have used both measurements and calculated the average in the presence of duplicates. 
The duplicates were both measured in the baseline sample obtained at the same time.  
We received data for n=619 participants and n= 695 individuals with metabolic syndrome.  A 
total of n=1218 study participants with IL8 measurement and genotype available were 
included.  
Participants of the MDC-CC study were genotyped using Illumina's OmniExpress chip. 
More details about the study participants for Study II are described in Figure 7. 
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Figure 7.  Flowchart of the recruitment of participants in the discovery and replication cohorts reported in study II 
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5.2 STATISTICAL ANALYSES 
The measured biomarkers were not normally distributed; therefore non-parametric methods 
(Kruskall Wallis test) were used throughout the four studies. The intravariability of the test 
was calculated directly from the MSD results and/or based on the average of all the standard 
deviations divided by the mean of the repeated values. A coefficient of variation >25% was 
considered as high according to the protocol. The intervariabiliy of the plate was calculated 
using the same formula.                                                                                                                    
When a coefficient higher than 25 was obtained, samples were repeated. If the coefficient of 
variation persisted, then samples were excluded from the analysis. 
Due to missing data in biomarkers and genotyping, some matching pairs in the case-control 
design were broken. Thus, we used unconditional logistic regression as the primary analysis 
in Studies I, II, and IV. Conditional logistic models were also evaluated yielding similar point 
estimates with wider confidence intervals. Odds ratios (OR) were interpreted as incidence 
rate ratios (IRR) (Studies I-IV), since controls were randomly sampled from the study base 
using density sampling. 
5.2.1 Study I 
Unconditional logistic regression analysis was used to estimate the OR (the odds of exposure 
among the cases divided by the odds of exposure among the controls). Because of 
unconditional models, we have adjusted in the crude model for the matching variables in the 
SHEEP design: hospital catchment area and age (5 years interval).  Sex was also a design 
variable, but results reported were sex specific. Further adjustments were done by factors 
considered as potentially confounding and for the traditional CV risk factors. 
The models were adjusted for hypertension, defined as individuals on antihypertensive drug 
therapy or with a blood pressure ≥140/90 mmHg based on measurements at physical 
examination (mean from two readings in supine position after 5 minutes of rest) or with a 
history of regular antihypertensive drug therapy during any part of the last 5 years (data 
from questionnaire). Diabetic participants were those with a B-glucose value > 6.7 or 
controlling diabetes with insulin and /or other treatment at physical examination. The cut-
off for hypercholesterolemia was a total cholesterol ≥ 6.46 mmol/L or receiving any lipid 
lowering medication.  Current smoking was defined as actively smoking in the two years 
preceding MI. BMI (kg/m
2
) was calculated from measurements at physical examination, 
CRP (mg/L) and insulin (μU/mL) were included as continuous variables.  Drug therapy 
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with statins, β-blocker and hormone replacement therapy (HRT) for women, were included 
as reported by questionnaire. 
For the SNPs association analysis, genetic effects of the three genotypes on the MI risk were 
unknown, thus models were constructed under the additive, dominant and recessive model of 
inheritance (113).   
In the recessive model, individuals carrying the homozygous minor allele (aa) were 
considered as exposed, and therefore compared to carriers of homozygous for the major allele 
(AA) and heterozygous group (Aa) (two minor alleles are necessary to predict the outcome).                 
In the dominant model, the assumption is that one minor allele is enough to predict the 
outcome, so carriers of the minor allele [homozygous (aa) and heterozygous (Aa)] were 
considered as exposed and compared to those homozygous for the major allele (AA).   
Finally, the additive model, considered that the effect of the heterozygote genotype (Aa) is in 
between the effect of the homozygote minor genotype (aa) and homozygote major genotype 
(AA).  
OR together with 95% CI were calculated, by means of unconditional logistic regression 
models, to evaluate the association for each SNP with MI matched on sex, age and residential 
area. Further adjustments for variables related to known CVD risk factors and inflammation 
were performed, though not with the intention to evaluate confounding effects but rather to 
investigate if the genotype-MI associations observed could be mediated by metabolic 
phenotypes. 
The analyses of the Hardy- Weinberg equilibrium were performed using the Chi-square test. 
Haplotypes counts and frequencies for the IL8 and IL8R genes were inferred from original 
genotype data  and the association with MI was calculated using the program THESIAS 
software version .3.1(114). 
5.2.2 Study II 
 From all the SNPs contained in the Cardiometabochip, only autosomal SNPs were included. 
Thus, n=116 SNPs in Chr 23 and n=119 mitochondrial SNPs were excluded as part of the 
data cleaning procedure.  
Quality control was based on the  following exclusion criteria: genetic variants with minor 
allele frequency (MAF) < 0.001  (n = 61,153 SNPs), since rare variables may hamper the 
model construction, and as a general rule as the MAF increases, so does the power (115).  
Highly significant deviation from Hardy-Weinberg equilibrium p<1x10
-5 
led to exclusion of
 
(n=1180 SNPs), variants with > 5% missing information due to missing information and 
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genotype call rates (n=3475 SNPs). Thus, a total amount of 121,445 SNPs were further 
considered for the analysis in this study. 
A Wald test was used to explore the association of 121,445 SNPs with log transformed IL8 in 
the SHEEP controls. The Wald test resembles a linear regression when applied to quantitative 
traits.  This stage 1 analysis was performed using PLINK software (version 1.07) (116). The 
genotypes for the five statistically significant SNPs who reached the pre-defined threshold 
value, defined as 1 x 10
-5,
 in the SHEEP controls, were extracted.   
Association between the selected SNPs and log IL8 values were calculated using a 
multivariate linear regression model (Beta (β) coefficients with corresponding 95% CI), 
under the assumption of an additive model of inheritance.  Point estimates were adjusted by 
sex using STATA software. The same procedure was performed for each of the replication 
cohorts (Stage 2), independently.  
When using  case-controls studies, it is possible that the differences observed are a result of 
underlying genetic structure in the population and not a result of a disease associated locus 
(population stratification) (117). Thus, in the SHEEP, we further adjusted for principal 
components in order to correct for possible population stratification.  Principal component is 
a statistical procedure that converts a set of observations of possibly correlated variables into 
a set of values of linearly uncorrelated values. 
OR with 95% CI were calculated, through unconditional logistic models, to evaluate the 
association between rs12075 and MI in the SHEEP. 
5.2.3 Study III 
In the nested case-control design from the 60YO cohort, OR with 95% CI using conditional 
logistic regression model were calculated for the association of IL8 with CVE. The analyses 
were focused on comparisons of the values above the upper quartile with the lower quartile.  
For the explorative analysis with CV mortality, serum IL8 median values were used as a cut-
off for comparison, due to the relatively few amounts of events.  
Potential confounding factors were defined as follows: diabetes at baseline was considered as 
having fasting plasma glucose ≥7.0 mmol/L and/or antidiabetic medication intake and/or 
having self-reported diabetes (108); Hypertension, defined as blood pressure ≥140/90 and/or 
antihypertensive drug therapy and/or self-reported hypertension (118); Hypercholesterolemia 
was defined as total cholesterol levels equal or above 6.45 mmol/L and/or treatment with 
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lipid lowering drugs. Smokers were defined as current smokers vs non-smokers or ex-
smokers. 
5.2.4 Study IV 
To evaluate the association between sIL6R and sgp130 with the occurrence of MI, OR with 
95% CI were calculated as estimates of IRR, using the same methodology as Study 1. 
Exposure for each biomarker was based on the cut-off value of the 75
th
 and the 90
th
 percentile 
of the distribution of the controls for the sIL6R and the sgp130, respectively. Only findings 
from the unmatched analysis were presented, as these were in close agreement with those 
from the matched analysis, yet allowed us to utilize all available information.  
5.2.4.1 Biological interaction 
The potential interaction between the two biomarkers exposures (sIL6R and sgp130) was 
analysed using departure from additivity of effects (biological interaction) according to 
Rothman and Greenland (119).  When one of the exposures  is preventive, such as sgp130 in 
our findings,   the variable should be recoded  such that the stratum with the lowest risk  
becomes the reference category for the co-exposure before calculating measures of 
interaction (120). Thus, the following model (Table 2) was constructed. 
 Absence of exposure to high 
sIL6R 
Presence of exposure to high 
sIL6R 
Absence of exposure to low 
sgp30 
Reference category RR high sIL6R 
Presence of exposure to low 
sgp130 
RR low sgp130 RR combined exposure 
Table 2.  Model for the analysis of biological interaction. RR: relative risk 
To quantify the amount of interaction, the attributable proportion (AP) fraction and the 
synergy index (S)  together with  95% CI were reported  (121).  In the interaction analysis 
sIL6R exposure was dichotomized into low ≤75th /high values >75th   and sgp130 levels in 
serum were dichotomized according to the median percentile of the distribution. Because of 
low number of double exposures for certain stratum, we decided to use the median as cut-off 
for the sgp130. Analysis using as a cut-off the 90
th
 percentile for the sgp130 distribution was 
also performed, yielding similar findings. 
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AP is the proportion of the incidence amongst individuals exposed to two interacting factors 
that are attributable to the interaction per se. AP greater than 0 indicates presence of 
interaction. An S index exceeding 1.0 indicates a synergistic effect, while an S index below 
1.0 indicates antagonistic effect. It is the ratio between the combined effect and individual 
effects. OR and 95% CI were calculated using STATA and the measures of interaction were 
computed using Epinet sheet (122).  
5.2.5 Selection of potential confounding factors 
In all the studies, a similar approach was utilized when considering potential confounding on 
the associations under study. Single, as well as adjustments for combinations of covariates 
were performed, in order to evaluate their impact on the results obtained. Moreover, some 
covariates included in multivariate models in earlier studies were also considered when 
deciding what covariate to include in the model. The rationale behind the selection of the 
main potential confounding factors based on á priori knowledge in this thesis is explained 
below.  
Cytokines             CVD 
   
  
                             Confounder                                                          
“A confounder must be associated with the disease (not with an effect of the disease) and 
with the exposure” (119) 
Smoking:  Nicotine has been reported to influence chemokine levels (123, 124). Diabetes: 
elevated concentrations of chemokines have been reported in diabetes type 2 (125, 126). 
BMI: elevated circulating cytokines has been reported among obese individuals (127). 
Hypercholesterolemia: Levels of cytokines and chemokines have been lowered in 
hypercholesteroleamic patients receiving statins. (128). Hypertension: cytokines have been 
implicated in the development and maintenance of hypertension (129-131).                              
The above mentioned factors have been associated with an increased risk of CVD (2).  
Additional adjustments for job strain (defined as low decision latitude but high psychosocial 
demands as determined by the Karasek-Theorell questionnaire), and physical inactivity 
(inactive leisure time) were also added as covariates, however not reported in the final models 
since its inclusion had little impact on the point estimates. Physical exercise has been reported 
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to reduce levels of IL8 after 12 weeks in patients with metabolic syndrome compared with 
baseline levels in a small group (132). Job strain has been associated to CHD risk after 12 
years of follow up in a working population and a significant interaction effect with job strain 
was observed for IL8 levels in a study from the MONICA/KORA-Augsburg (133). It has 
been reported that cortisol may influence inflammatory responses via the hypothalamic 
pituitary adrenal axis through the induction of IL8 (134) and that epinephrine stimulates IL8  
levels in samples containing platelets and stimulated with LPS (135).  
CRP: CRP could be considered as an intermediate phenotype for IL8 and IL6 receptors, 
rather than a potential confounding variable. In Study 1, we had adjusted to observe if the 
findings indicated mediation. 
Population Stratification: In Study II, different allele frequencies in a group of participants 
may be due to an ancestry difference, therefore population stratification may lead to a higher 
chance of finding spurious association and a lower chance of detecting true effects. Although 
the SHEEP population involves mainly citizens of Swedish origin, we initially include the 
first two PCs as covariates in the linear regression model in order to correct for population 
differences regarding SNPs that appear to be associated with disease. We did not see 
differences in point estimates, and adjustments without PC were reported.   
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6 RESULTS 
6.1.1 Study I 
Compared to lowest quartile of circulating IL8 in serum, study participants exposed to the 
highest quartile of IL8 were associated with a reduced occurrence of MI, particularly in 
women unadjusted OR 0.44 (95% CI 0.3-0.7). This association holds true after addition of 
potential confounders as covariates in the model. 
The T allele at rs4073 was associated with a slight increased risk of MI under the additive and 
recessive model of inheritance, adjusted OR (95% CI) 1.2 (1.0-1.4) and 1.3 (1.0-1.7), 
respectively. In the stratified analysis, we saw an indication of effect measure modification 
where this association was only observed in men. Similarly, diplotypes carrying the T allele 
were associated with an increased risk of MI in men. 
Variants in the genes encoding IL8 receptor were not associated with the risk of MI. 
No statistically significant differences were observed among the serum levels of IL8 across 
the different genotype of each of the 5 SNPs for the IL8 and IL8R genes studied in the 
SHEEP controls. It should be pointed out however that the lack of association with MI for 
these SNPs cannot be totally excluded, it may be that effects are small and that insufficient 
power did not permit detection of an association in the present study. 
Compared to other biomarkers measured in the SHEEP, we observed a statistically 
significant difference in IL8 levels measured in cases at different time points after the disease 
onset, particularly in women. 
6.1.2 Study II 
From the 121,445 SNPs that passed quality control, five SNPs (rs12075A/G mapping at 
chromosome (Chr) 1, rs13179413C/T at Chr5, rs6907989T/A at Chr6, rs9352745A/C at Chr6 
and rs1779553T/C at Chr14) were associated with log transformed IL8 in serum at a p-value 
< 1x10
-5
  in the discovery stage, with the strongest association SNP (rs12075 A/G, unadjusted 
p value 1.6 x10
-6 
) mapping at the DARC gene.  
These five SNPs were carried forward to in silico replication in the PIVUS, MDC-CC and 
SCARF studies. Replication was defined as a p-values <0.05 for the association evaluated in 
the independent populations. 
The MAF for each SNP were rather similar across the different populations. Consistent with 
observations in the SHEEP, the association observed between SNP rs12075 with log serum 
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IL8 levels was replicated in the PIVUS study (p=0.0006), where a 10.4% reduction in IL8 
was observed in the presence of the G allele. These findings were not replicated in the 
MDCC-CC and SCARF studies. 
Similarly, the association observed at the other 4 SNPs could not be replicated in serum nor 
plasma in the different studies. 
Homozygous   carriers of the G allele at rs12075 SNP had lower serum median (IQR) IL8 
levels  (AA =17.1 (9.9-24.6) pg/mL;  AG =13.5 (8.9-20.8)  pg/mL; GG=11.2 (7.4-16.9)  
pg/mL) in the SHEEP and in the PIVUS (AA =7.2 (5.0-10.7) pg/mL;  AG =6.3 (4.5-9.0)  
pg/mL; GG=6.0 (4.0-8.3)  pg/mL) studies. The decreasing trend of IL8 in plasma was similar 
across the SCARF and the MDC-CC studies, although there was no statistically significant 
difference. 
Further, IL8 was measured in plasma in a random subset of the SHEEP individuals where 
samples were available. In this group, no association was observed between the 5 SNPS with 
log IL8. 
We did not observed an association between the SNP rs12075 and the risk of MI in the 
SHEEP using the additive OR 1.0 (95% CI 0.9-1.1), dominant OR 1.0 (95% CI 0.9-1.1), or 
recessive OR 1.1 (95% CI 0.9-1.1) model of inheritance, after adjusting for the matching 
variables of the study. 
6.1.3 Study III 
In the crude analysis, exposure to high levels of IL8 (highest quartile) were not associated 
with increased risk of CVD in both women and men, unadjusted OR (95% CI) 0.8 (0.4-1.5) 
and 1.0 (0.7-1.6) respectively, compared to the lowest quartile. Further adjustments for 
hypertension, diabetes, hypercholesterolemia, BMI and current smoking did not lead to major 
changes in the point estimates. 
An interesting finding was indication of an association between high serum levels of IL8 and 
CV mortality, particularly in men, when using the 50
th
 percentile as a cut-off (confidence 
intervals, though, were wide and overlapping one): OR of 2.4; 95% CI (0.8-7.1). However, 
the power to detect such association was rather low, especially in women.  
6.1.4 Study IV   
 Exposure to high serum sIL6R was associated with increased occurrence of MI, even though 
the associations were weakened after adjusting for possible confounding factors.  Using as 
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cut-off limit the 75
th
 percentile value in the control group, the OR was 1.4 (95% CI 1.1-1.8) 
after adjustments for age, residential area, hypertension, diabetes, hypercholesterolemia, BMI 
and smoking. Even higher point estimates were observed when using the 90
th
 percentile value 
in the control group as the cut-off limit OR: 1.7 (95% CI 1.2-2.3). Conditional logistic 
regression models were also evaluated, yielding similar point estimates as the unconditional 
models: OR was 1.5 (95% CI 1.2-1.9) for the crude model and in the adjusted model OR was 
1.4 (95% CI 1.0-1.8).  
For levels of sgp130, there was no association with MI when using, as cut-off limit, the 75
th
 
and the 90
th
 percentile value in the control group in the crude analysis. However, after 
adjustments, exposure to very high sgp130 (>90
th
 percentile) was associated with a reduced 
occurrence for MI, OR 0.68 (95% CI 0.5-0.9). Particularly, adjustments for diabetes and 
hypertension led to lower ORs and CIs suggesting their influence as confounding factors.    
There was an indication of a possible biological interaction for the co-exposure to sIL6R and 
sgp130. High sIL6R levels (>75
th
 percentile) and low sgp130 (below the median) yielded S 
index point estimates of 1.7 (95% CI 0.5-6.1) and an AP fraction of 0.19 (95% CI -0.2 – 0.5).  
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7 DISCUSSION 
7.1.1 Circulating IL8 and cardiovascular events 
Study I indicates that elevated levels of IL8 were associated with a decreased occurrence of 
first time MI in a population aged 45-70 years old living in Stockholm. At the same time, 
high levels of IL8 were not associated with increased risk of CVE in a cohort of 60 years old 
men and women from the Stockholm area (Study III).   
Findings from population-based observational studies investigating the association of IL8 
with CVD risk appear inconsistent across countries, materials and methodological approaches 
(72, 73). In addition, published studies are few, likely due to publication bias since this has 
been pointed out as a major challenge in biomarker research (136, 137). Publication bias 
arises when published findings differs from the results of all the unpublished research that 
has been done in an area.  
When comparing the present results to previous studies, several aspects including study 
design, endpoints, length of follow-up, as well as potential confounding factors must be taken 
into consideration. 
7.1.1.1 Study design 
Sampling in the SHEEP was performed at least 3 months after MI, at which time, metabolic 
stability should be regained (138, 139).  
To interpret our findings in the context of our population, we have characterized the trend of 
IL8 in cases sampled at different times, comparing levels of median IL8 analysed according 
to sampling time-frame. Whereas other biomarkers previously reported in the SHEEP such as 
IL6, CRP, TNF-α seemed to be rather stable in cases across sampling times, the pattern of 
IL8 appears to differ according to sampling date, particularly in woman. This analysis, 
though, needs to be interpreted with caution, since these are not case repetitive measurements 
and the inter-individual variability was not taken into account. In addition, it might well be 
that those with a more “severe” form of disease attended the clinical investigations earlier or 
later as compared to the rest of cases, although this cannot be determined.  
A second way in which the event itself might have influenced the exposure levels is with 
regards to medication post MI. Therapy prescribed for secondary prevention, in particular 
with acetyl salicylic acid (ASA), might influence the levels of IL8, and therefore potentially 
confound the association we observed in the SHEEP. Indeed, at a dose -response, ASA has 
been shown to down-regulate IL8 at the mRNA and at the protein levels in TNF-α stimulated 
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HUVEC (140). The lower levels of circulating IL8 observed in cases as compared to controls 
might be in relation to the large proportion of cases with ASA. However, at low doses, aspirin 
exerts mostly antithrombotic rather than anti-inflammatory effects (141). Little is known with 
regards to the role of circulating IL8 in arterial thrombosis and the effect of thromboxane 
inhibition by aspirin on circulating IL8. In this context, other investigators have found 
increased expression of IL8R in platelets obtained from patients with inflammatory bowel 
disease (142). At the same time, IL8 has been shown to inhibit megakaryocytopoiesis 
suggesting its involvement in platelet modulation and activation (143).  
In light of the unexpected findings with the SHEEP (Study I), we have sought to further 
adjust for medication therapy.  Inclusion of these covariates had little impact on the results.  
In conclusion, reverse causality as an explanation to findings from the SHEEP cannot be 
entirely ruled out. Interestingly, the association of IL8 with CVD in the 60YO, where the 
exposure was collected before disease onset, showed point estimates rather consistent with 
the SHEEP findings particularly in women, although with wide confidence intervals. 
7.1.1.2 Differences in Cardiovascular Endpoints 
For the purpose of increasing power in a single endpoint, often in epidemiological studies, 
fatal and non-fatal CVE are combined. Unlike other cohort design studies, the results from 
the SHEEP study are restricted to non-fatal MI.  The EPIC Norfolk study had a composite 
outcome of non-fatal and fatal CAD, defined as participants who had a hospital admission 
and/or died with CAD as underlying cause using the 9
th
 ICD codes 410 to 414. These codes 
identified acute MI, angina pectoris and other forms of CHD.  On the other hand, the 
MONICA/KORA Augsburg study defined the outcome as incident fatal, non-fatal MI and 
SCD before age 75. The cohort of 60YO defines a composite outcome of fatal and non-fatal 
MI, hospitalization due to angina pectoris as well as fatal and non-fatal strokes. 
Although all these events may share common aetiology, it is still unknown if the difference 
among fatal and non-fatal outcomes is only in severity or whether there are subtle differences 
in the underlying mechanisms.  High levels of IL8 were associated with a slight  increased 
risk of all-cause mortality in a Swedish cohort of elderly women  from the PIVUS study 
(144). Furthermore, in a secondary analysis from the CORONA trial, IL8 was associated with 
increased risk of all-cause mortality (75). As a result, survival bias might explain at least part 
of the discrepancy in findings from the SHEEP study, as compared to earlier studies.  We 
observed an indication of an association of IL8 with CV mortality in the 60YO cohort and it 
is tempting to speculate that CV mortality might have been a driving force in the associations 
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previously reported. Nonetheless, our study comprises few CV deaths and further studies are 
needed to confirm this hypothesis.  
At the same time, the 60YO cohort includes, as an outcome, ischemic stroke, a disease that 
shares common features with the pathophysiology of MI (145). IL8 levels has been reported 
to be elevated in atrial fibrillation, a condition that predisposes to stroke and trombo-
embolisms (146). Yet, to the best of our knowledge, the association of IL8 with angina 
pectoris and stroke is unknown. Noteworthy, in the 60YO cohort, IL8 at baseline did not 
differ significantly among MI, angina pectoris and ischemic stroke, thus, the use of a different 
composite outcome might not fully explain the differences observed.  On the contrary, IL8 at 
baseline from fatal cases was higher as compared to the rest of the study population. 
Inflammatory biomarkers may not be causally related to CV death. Instead, our results could 
support the hypothesis that inflammatory biomarkers, at high concentrations, may reflect 
subclinical disease or “biological ageing (147) . Previous epidemiological studies in the 
elderly have underscored the notion that risk estimation in elderly people may warrant an 
altogether different approach than in young and middle aged subjects, since inflammation 
(IL6, CRP) has been found to be associated with a graded risk of all-cause and CV mortality 
in elderly men (148). In addition, IL6, CRP and to a lesser extent, fibrinogen are more closely 
associated with the risk of fatal MI or stroke than to non-fatal CVE in the elderly (149). The 
reason why the association between IL8 and CV mortality was predominantly observed in 
men after adjusting for traditional cardiovascular risk factors in Study III is unclear. 
Overall, the overriding influence of age in a “cohort of survivors” may have underestimated 
any of the associations, suggesting that it may be differences in risk factor patterns, perhaps 
with regard to inflammatory biomarkers between fatal and non-fatal events. Consequently, it 
may be necessary to dissect association of IL8 with fatal and non-fatal events. 
7.1.1.3 Differences in baseline characteristics 
It is plausible that IL8 measurements at baseline may mirror a chronic inflammatory state, 
such as cancer or other chronic inflammatory diseases not yet diagnosed at the time of 
enrolment. It is possible that improved survival in CVDs in developed countries (150) is 
accompanied by an increased risk of cancer incidence and mortality. 
In Study 1, the decreased occurrence of MI with high IL8 levels was observed particularly in 
women. Speculatively, some of the potential mechanisms that may explain these findings are 
the decreased concentration of estradiol accompanied in the transition from perimenopausal 
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to postmenopausal stage. IL8 has been reported to increase after menopause and has been 
correlated with symptoms such as hot flashes (151, 152).  However, our findings were not 
explained by the use of HRT.  Approximately 43% of women in the 60 years old cohort were 
under HRT and adjustments for this variable did not change the point estimate either.  
IL8 release has been shown to be higher in human visceral adipose tissue as compared to 
subcutaneous adipose tissue (153). Women tend to have a higher percentage of subcutaneous 
fat than men, despite comparable amounts of visceral adipose tissue (154). However, aging 
has been reported to increase the visceral adipose tissue with weight gain in women (155). In 
study 1, we have further adjusted for waist circumference and the point estimates did not 
change substantially. 
7.1.1.4 Experimental studies 
Experimental studies in animals have been hampered by the fact that, to date, a homologue of 
human IL8 has not been identified in rodents, (156) although human IL8 is partially 
functional on the corresponding  IL8R in mouse (157). Thus, translation derived from in vitro 
studies in clinical setting remains to be elucidated. 
Experimental evidence has also indicated that IL8 prompts tissue protective effects during 
ischemia reperfusion injury (158), wound healing  (159) and tissue remodelling (62).  
7.1.1.4.1 IL8 isoforms 
IL8 isoforms seem to display heterogeneity with respect to chemotaxis of inflammatory cells.  
Studies in rabbits indicated that in vitro, the [Ser-IL8]72 isoform is approximately 10 fold 
more potent than the [Ala-IL8]77   in inhibiting adhesion of neutrophils to IL1 activated 
cultured ECs (67, 70). Nevertheless, in vivo, these observations were not consistent, since 
intradermal administration of both isoforms produced equipotent results (67).  Another study 
in a model of intradermal inflammation in rabbit, reported that intravenous administration of 
the IL8-77 isoform inhibited progressively polymorphonuclear (PMN) accumulation  (160), a 
similar finding for the 72 isoform in a dose-response .  However, when injected into the 
dermis, both isoforms showed PMN accumulation with comparable activity. In neonates, 
while inhibition of total IL8 decreased chemotaxis, the inhibition of IL8 77 has no effect (71). 
Thrombin stimulates production of IL8 (161, 162) and, together with plasmin, efficiently 
converts [Ala-IL8]77   to [Ser-IL8]72 (70, 163). Antithrombin III inhibits the conversion of 
[Ala-IL8]77  (160). Dysfunctional endothelium may exhibit procoagulant  properties and can 
potentially generate thrombin (160) , and therefore the conversion of [Ala-IL8]77  to the more 
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potent isoform may occur at the interface of the vessel wall and blood in sites of 
inflammation.  
Altogether, it could be conceivable that a shift of isoforms might partly explain the results 
obtained in epidemiological studies. Thus, it may be of interest to estimate the proportion of 
circulating isoforms in population based studies and during acute inflammatory conditions, as 
well as to explore if there are isoform differences in terms of affinity to both receptors. The 
heterogeneity in epidemiological findings reported so far for IL8 and risk of CVD raises the 
possibility that it could be related to different proportions of circulating isoforms. 
In a broader perspective, all these observations may prompt  the hypothesis that the 
pleiotropy of  IL8 activities exhibited  depends on whether this chemokine is active 
extravascularly or intravascularly  (160). It might well be that the proinflammatory properties 
of IL8 are related to intraplaque and intralesion activity, while the regulation (anti-
inflammatory IL8) is driven by the circulation. Therefore, circulating IL8 might not be a 
proxy for in situ inflammation, and the lack of associations would not preclude the local 
chemokine effect on coronary arteries and atheromas. 
7.1.1.4.2 IgG and DARC  
Furthermore, studies conducted during the 90´s have reported a neutralizing antibody (IgG) 
that binds to IL8 in serum. This complex (IL8-IgG) is not able to bind to IL8 receptors in 
neutrophils and possibly to human erythrocytes in vitro (164, 165).  
Although the functional significance of these antibodies are unknown, it is plausible that, 
along with erythrocyte sequestration by DARC, stored IL8 limits the biological effect of IL8 
that gains access to the circulation. These mechanisms may facilitate the elimination of 
residual IL8 not internalized by erythrocytes. Regardless of their physiologic role, these 
antibodies are potentially confounding variables in the quantification of IL8 in biological 
fluids as they may compete in immunoassays or bioassays used to detect IL8. 
7.1.2 Genetics variants of IL8 and risk of MI  
Genetic association studies of a particular genetic variant are challenging. Furthermore, the 
effect of alleles at a given gene may depend on the combination of genes at other loci not 
being studied, and therefore alter the strength of the association (76). 
Since there is no phenotype data to hint at an indication to use one inheritance model over 
another, the multiple models  approach was used to investigate the genetic variants (166).  
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In study I, a candidate gene (i.e. hypothesis driven) approach was used to identify SNPs 
potentially associated with the regulation of IL8 as well as with the development of MI. We 
have observed that a promoter genetic variant at the IL8 gene was associated with a slightly 
increased risk of MI under an additive and recessive model of inheritance. Consistently with 
these results, the same variant was associated with an increased  risk of ACS using a co-
dominant model in a Chinese Han population (85).  On the contrary, in a Caucasian 
population with CAD, the common AA251TT781 genotype of the IL8 gene was associated with 
a reduce risk of ACS (84). In the latter study, the reference category was those with the most 
common genotype. However, most studies were small in size, and the majority of the 
reported findings are unconfirmed. The same genetic variations have been involved in the 
susceptibility to a large number of inflammatory diseases and allele frequencies show 
diversity in the different ethnic groups (167-169), an observation that has been previously 
highlighted by others (170, 171). Of importance in the interpretations of these findings is that 
a considerable amount of missing genotypes was observed for the SHEEP. The missing 
genotypes were randomly distributed in cases and controls. However, the MAF of the SNP 
rs4073/-251A>T in the SHEEP was comparable to the frequency reported in other European 
populations (172, 173), but not to that reported in the Hapmap and the 1000 genome projects. 
Haplotype analysis uses additional information regarding the linkage between genetic 
variants mapping at the same gene. For example, even though rs4073 is situated at the 
promoter region, it may, through linkage with other polymorphisms, located within other 
regulatory or coding regions, affect gene transcription or function resulting in interindividual 
variation in levels of cytokine production/activity. Results of haplotype frequency estimation 
for two-SNP combination at the IL8 gene (rs4073A/T-rs2227306 C/T) suggested that 
diplotypes carrying the T allele at the two SNPs were associated with an increased risk of MI, 
particularly in men.     
In study I, IL8 levels did not differ significantly across genotypes in the control group at each 
of the IL8 gene and IL8R gene. Published studies in this respect are scarce. An earlier study 
on biopsy specimen from mucosal IL8 levels of the gastric body have reported that, as 
compared to the T allele, carriers of the A allele of the rs4073 had significantly higher IL8 
protein (174), and similarly, experimental data suggested that the A allele is associated with 
increased IL8 production (172). Carriers of the TT genotype where presumed lower IL8 
production is observed had a poorer survival for follicular lymphoma (175). All these 
observations underscore the complexity of disrupted pathways in IL8. However, cautious 
interpretation of these findings is necessary, due to lack of replication.  
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In light of these latter observations, Study II has sought to investigate the genetic 
determinants of IL8 using SNPs contained in the Cardiometabochip.  In controls belonging to 
the SHEEP study, the SNP rs12075 coding DARC gene was associated with log transformed 
values for IL8.  Lower values of IL8 were observed in the presence of the G allele. While the 
association was not at a GWAS level of significance, the findings were replicated in 
independent sample sets. 
DARC, recently named as an atypical chemokine receptor (176), is expressed in erythrocytes, 
post-capillary ECs and Purkinje cells. DARC shares two interesting features: first, it lacks the 
DRY motif that is required for signal transduction, acting as a “silent decoy receptor” and it 
only binds angiogenic, but not angiostatic, chemokines. Therefore, DARC may act as a key 
regulator of IL8 highly dependent on its localization: in erythrocytes, this protein serves as a 
reservoir for IL8 whereas in ECs it may facilitate IL8 translocation through the vessel wall 
(177, 178).  IL8 bound to erythrocytes is not bioactive and this mechanism may play an 
important role in controlling the inflammatory response driven by this chemokine (179).  In 
the present context, such binding may have had an appreciable impact on the amount of 
circulating IL8 detected and might hamper the interpretation of measurable IL8. 
The previous findings evoke testable hypotheses regarding the role of DARC genetic variant 
in CVD by damping inflammation (180). Thus, we have evaluated rs12075 SNP in relation to 
MI in the SHEEP, where no association between DARC and MI was observed.  Although this 
genetic finding has, as yet, not been replicated in other studies, previous genetic consortia 
have not reported an association between this particular SNP and the risk of CVE.  However, 
it is uncertain if one may find a lack of association considering atherosclerosis as an outcome. 
IL8 has been found in atherosclerotic plaques (54) and it is further conceivable that those 
carriers of the minor allele might have a lower risk of developing atherosclerosis. 
An intriguing finding was the fact that the association of rs12075 with IL8 could only be 
replicated in the cohort where IL8 was measured in serum. We did not investigate in depth 
the molecular mechanisms to clarify these genetic differences that were observed. We did, 
however, measure IL8 in plasma samples in a subset of the SHEEP controls with available 
measurements of IL8 in serum, and the findings could not be replicated. Serum is plasma 
without the clotting factors. Neither plasma nor serum contains red or white blood cells or 
platelets. A comparison of serum and plasma IL8 has shown much higher levels in the former 
possibly, because like other chemokines, IL8 might be released on platelet activation during 
clotting (181, 182).  
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Currently, there is no consensus of which biological fluid provides more accurate assessment 
or standardized procedures for IL8. In line with these results, it has been suggested that 
chemokine release upon platelet activation during the clotting process makes serum 
measurements artefactually high, (183), making plasma a better choice. On the other hand, 
low levels of chemokines lie at the current limit of detection of many available assays, thus 
serum assessments may give greater sensitivity. It could be conceivable that IL8 serum levels, 
corrected for the blood platelet count, might be the best way to assess IL8 circulating in blood 
(184). 
 
7.1.3 Circulating sIL6R and sgp130 and risk of MI  
7.1.3.1 sIL6R 
Considering that many cytokines orchestrate a specific biological response, it seems 
reasonable in epidemiological studies to investigate multiple cytokine within a particular 
family in order to enhance our understanding of the inflammatory response (185).  Therefore, 
studies of the two other constituents of the IL6 trans-signalling (sIL6R and sgp130) may give 
more precise information about the activation of the IL6 pathway (186).  
We have observed an increased susceptibility to MI in individuals exposed to high sIL6R in 
the SHEEP.  No dramatic influence by any specific covariate was observed. However, a 
number of covariates had moderate influence on results, but often only in combination with 
other covariates.  
In agreement with these results, elevated levels of sIL6R have been observed in patients with 
MI (103), CHD (187), in elderly men with metabolic syndrome, endothelial dysfunction, 
arterial stiffness (188) and in other inflammatory diseases such as anti-citrullinated cyclic 
peptide antibody in rheumatoid arthritis (189).  In addition, experimental studies have 
implicated IL6 trans-signalling in the pathogenesis of Chron disease (190), pulmonary 
fibrosis (191) and colorectal cancer (192).  However, evidence from population-based studies 
is lacking. 
 Recently, Rose-John and colleagues has widely discussed a buffer system underlying the 
trans-signalling, where sIL6R and sgp130 form a buffer for IL6 in the circulation (93). Under 
this premise, sIL6R will bind with an affinity of around 1nM to IL6 and once the complex is 
formed, it will bind to sgp130 with 100 times higher affinity (10 pM) to neutralize the 
complex (193). It could be speculated that in the SHEEP, the sIL6R measurements mirrors 
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the sIL6R/IL6 complexes that are activating the trans-signalling. Another interpretation, 
might well be, that cases would have higher “free” sIL6R to bind IL6 to activate the trans-
signalling. The measurements in the present study, however, cannot distinguish the complex 
sIL6R/IL6 and sIL6R. 
7.1.3.2 Sgp-130 
Different cut-off values were used for evaluating the association of these biomarkers with MI. 
When using different cut-off values based on the 75
th
 and 90
th
 percentile, no association was 
observed in the crude models. Only very high levels (>90
th
) of sgp130 were associated with a 
reduced occurrence for MI in the adjusted model, suggesting the influence of potential 
confounders in this association. When adding the covariates to the regression model one by 
one, diabetes was observed to have the largest impact on the point estimates. Associations 
have been reported between plasma sgp130 levels and metabolic syndrome in an elderly 
community, possibly mediated by insulin resistance (186).  Furthermore, serum sgp130 was 
inversely associated with insulin sensitivity in women with polycystic ovarian syndrome 
(194), suggesting a complex interplay of the trans-signalling in different metabolic 
conditions.  
As for the sIL6R, the sgp130 measurements were not able to determine the “free” circulating 
levels, from the sIL6R/sgp130/IL6. One may speculate in both cases, that inhibition of the 
trans-signalling pathway may be associated with a reduced susceptibility to MI. 
7.1.3.3 Biological interaction   
Knowledge of potential interaction between two biomarkers would certainly contribute to 
direct, experimentally orientated research towards important biological mechanisms.  The 
measures of interaction presented in Study IV, possibly suggest the presence of biological 
interaction among the two co-exposures.  It must however be noted that evidence of 
synergism or antagonism with this analysis requires larger study materials than the present to 
obtain more stable estimates. 
It has been discussed that blocking the IL6 trans-signalling, while maintaining the 
physiological classic signalling, holds the promise of developing selective trans-signalling 
inhibitors. In fact, a recent study demonstrated that inhibition of the trans-signalling of IL6 
through the administration of sgp130 significantly reduces the development and progression 
of atherosclerotic plaques in mice, by neutralizing IL-6/sIL6R complexes without  affecting 
classic signalling, i.e., acute phase response and cholesterol levels (101).  Recombinant 
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proteins that mimic the property of sgp130 have been developed and are currently in clinical 
trials for the treatment of inflammatory diseases (195).   
As outlined earlier, a SNP causing an Asp328Ala aminoacid change in the membrane bound 
IL6R has been identified.  Remarkably, carriers of the minor allele of the Ala358 present 
lower levels of CRP (51, 196) but at the same time elevated levels of IL6, sIL6R (96, 97, 
197), and yet are less susceptible to type I diabetes and CHD (51, 96-98). In this context, 
increased levels of sIL6R appear to have an anti-inflammatory impact. More recently, IL6R 
haplotypes has been reported to regulate serum levels of CRP, IL8, sIL6R and fibrinogen 
(198), suggesting a complex interplay in the regulation of inflammation. 
  
 50 
8 METHODOLOGICAL CONSIDERATIONS 
 
Strengths 
The major strength of case-controls studies such as the SHEEP is the large number of 
subjects with available extended exposures information and biological samples.  Furthermore, 
this design offers an alternative that is much more efficient compared to the corresponding 
cohort.   
The high participation proportion of those invited to participate in the cohort of 60YO allows 
this study to be representative of 60 years old women and men from the Stockholm area with 
complete follow-up. The combination of a large study sample and high costs for new 
technologies makes it unfeasible to measure new markers on an entire cohort. Thus, an 
additional strength of the nested case-control lies in reducing the cost of exposure assessment 
in the prospective cohort. 
 These studies were carefully designed and controls were randomly sampled from individuals 
at risk, at the times when cases were identified. With this approach (incidence density 
sampling), controls mirrors the exposure frequencies in the study base that generated the 
cases. By matching procedures, the aim was to prepare for a more efficient stratified analysis. 
Increased efficiency is achieved if there is a strong association between the matching factor 
and the disease under study. However, matching implies that is not possible to investigate the 
associations between the matching factors and the disease of interest. 
Reverse causality  
Temporality (exposure precedes the outcome) is an issue to consider in a case-control study, 
where sampling was performed at least 3 months after the MI event. In Studies I and IV, one 
cannot be certain that the serum concentration of biomarkers observed truly reflected the 
exposures before disease onset. It is therefore not possible to draw conclusions on causal 
relationships between the exposure and the disease. However, in young post MI patients, 
Hamsten and co-authors have shown that some biomarkers regain metabolic stability 3 
months after the disease onset (138, 139).  This is supported by the level of other biomarkers 
reported in the SHEEP (IL6, TNF alfa, fibrinogen), which are comparable to baseline levels 
of prospective studies (87, 199, 200).  This potential source of error, may lead to an over or 
underestimation of the OR which is not possible to correct in data analysis.  However, the 
genotype variables in Study I are unlikely to be affected by this potential source of error. 
  51 
It is likely that cases follow preventive measures recommended by the physician after the 
index event. It is therefore reasonable to believe that changes in lifestyle pattern e.g., physical 
activity, diet and smoking cessation post MI may influence levels of biomarkers under study. 
On the other hand, a recent systematic review reported insufficient evidence for the effect of 
physical activity on IL8 (201) . Diet components such as Vitamin D, has been shown to 
decrease IL8 secretion from preadipocytes (202). Such changes might have yielded 
underestimated results. 
The proportion of hypertension was lower in cases as compared to controls. Blood pressure 
commonly falls after an MI event due to damage in the myocardium and might, to some 
extent cause an underestimation in patients. Other medication such as statins, and beta-
blockers, mainly prescribed in cases, could possibly have an influence on the levels of IL8 
(128). However very few individuals were receiving statins, since the first large scale 
cholesterol lowering trial suing statins was yet to be published by the time the SHEEP data 
collection was performed (203).  In human carotid atherosclerotic plaques,  lower neutrophils 
were observed among individuals using beta-blockers as compared to non-users, and at the 
same time high neutrophil numbers were associated with high levels of IL8 (204).  
Thus it is important to consider the potential inherent bias linked to the retrospective post-
event data collection. 
Measurement aspects 
In the SHEEP and the cohort of 60YO, samples contained at bio-banks were frozen over a 
long period of time before analysis. The number of epidemiological studies involving 
prolonged blood storage is overflowing. Such investigations using different biomarkers 
stored at biobanks have yielded comparable associations with CVD risk (at least as strong as 
in former studies), which strengthen the case against underestimation due to sample 
degradation (205). Yet, to date, there is no available epidemiological study aiming to 
investigate this issue. It is likely that in this scenario, the misclassification would occur, with 
more or less, equal frequency regardless of the disease status. Non-differential 
misclassification of a dichotomous exposure biases toward the null (Studies IV). However, if 
the exposure is not dichotomous, then non-differential misclassification may bias the estimate 
either toward the null or away from it, depending on the categories into which participants are 
misclassified (Studies I, II and III). 
All the biomarkers of the present study were measured at a single time point. In Study III, the 
possible fluctuations in biomarkers over time may yield biased estimates of the true 
 52 
association (“Regression dilution”) (206). Such bias is likely to be non-differential leading to 
attenuation of the true associations.   
In addition, in the SHEEP study n=121 samples and n= 3 samples were thawed once and 
twice respectively. In order to minimize the potential source of error, time of defrosting was 
handled similarly among cases and controls Adjustments for number of thawing occasions 
did not alter our findings and it was randomly distributed among cases and controls.  
Non-participation 
In epidemiological studies, non-participation may result in selection bias. Selection bias 
arises when participants selected are different from those not participating.  
In general, the high participation proportions in the SHEEP and the cohort of 60YO studies 
make them less vulnerable for selection bias. Still, it might be possible that non-respondents 
differ from respondents with regard to their pattern of exposure. In the SHEEP, for instance, 
controls had a lower participation proportion as compared to cases. If such differences are 
present, differential non-participation may yield underestimated results. 
One may argue that not all samples from the original SHEEP design were analysed. However 
the lack of enough serum samples with regards to each biomarker was similarly, and 
randomly, distributed among cases and controls, so it is unlikely that a selection bias might 
have an impact in our estimates. Nevertheless, in the genetic analysis for the promoter SNP 
rs4073, a considerable amount of study participants were missed, therefore we cannot 
exclude the possibility that these results might be due to chance. Further replication in 
independent cohorts is warranted. 
In order to address the question of a potential selection bias introduced by the proportion of 
individuals excluded due to missing samples in study IV, baseline characteristics from these 
study participants were re-analysed. Compared to the entire SHEEP population, those 
participants who were excluded were slightly younger. Hypertension was slightly more 
prevalent in controls as compared to cases, an observation consistent with the SHEEP 
population. Sex distribution, BMI, diabetes, hypercholesterolemia, physical inactivity and 
smoking presented similar prevalence. 
The practically complete to follow-up (99.8%) of the 60YO through linkages to various 
population-based registers minimize the possibility that our results were subjected to 
differential loss to follow-up. 
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Misclassification of Exposure 
Measurements processes were conducted blinded with regard to case-control status, in order 
to minimize the “observer expectation bias” in the nested case-control of the 60YO. In the 
majority of occasions, the SHEEP samples were placed in a similar proportion with regards 
to case-control distribution in each plate, and were read in a “blinded” way by the machine. 
Systematic genetic differential misclassification of exposure is unlikely. 
Recall bias 
Cases may recall exposures differently at the time of filling in the questionnaire compared to 
controls. This is an inherent limitation of case-control study designs, such as in the SHEEP. 
The exposures under study in this thesis were not collected through questionnaire; however, 
covariates such as smoking were reported through questionnaires. Any potential 
misclassification in respect of confounders should also be taken into consideration. 
Survival bias 
The inclusion of only non-fatal MI events may not truly generalize our results on fatality 
cases (n=603) in the SHEEP study. However, due to the study design it was impossible to 
perform sampling on fatal events. Data regarding biomarkers of fatal cases from large 
epidemiological studies are quite rare. This raises the question whether the exposures studied 
in this thesis are different (lower) from those in fatal outcomes. One may therefore keep in 
mind that the ORs in Studies I, II and IV may be an underestimation of the impact of these 
biomarkers on the occurrence of MI. 
Misclassification of Disease 
From the period when the studies included in this thesis were conducted up to now, more 
sensitive and specific diagnostic methods for MI have developed.  Although, these new 
diagnostic criteria will be more sensitive for smaller MIs, clinically silent MIs are still 
frequently in advanced CHD. Thus, it is important to consider that MI cases considered in 
these studies refer to only those clinically diagnosed, which may only reflect a subset of all 
MIs. Such silent infarctions, if present, were not excluded from the study base, since they 
could not be ascertained amongst the participants of the present studies. 
Residual and unmeasured confounding 
When studying inflammatory biomarkers, it is reasonable that they might also mirror 
inflammatory conditions that are not in the scope of the study. In fact, cytokines have been 
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associated with several cancers and other inmunoinflammatory diseases (207, 208). We did 
not adjust for these inflammatory conditions since, unfortunately, we did not have specific 
information.  As well, environmental factors with potential influence on the biomarkers in 
this study were not considered in this thesis. The presence of unknown confounders cannot 
be excluded. 
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9 CONCLUSIONS AND FUTURE PERSPECTIVE 
The current findings of this thesis may have implications for understanding disease 
mechanisms and for further research strategies.  
In a population of 45-70 years old, elevated levels of IL8 in serum was associated with a 
reduced occurrence of non-fatal MI. Furthermore, no association was observed with a 
combined endpoint of fatal and non-fatal CVE in a 60 years old population; however there 
was an indication of a possible association between IL8 with risk of CV mortality.  
This finding may suggest that IL8 might serve as a marker of disease severity in older adults, 
but not to the same extent in younger population, free of prevalent MI. In this context, the 
question arises as to whether levels of IL8 reflect inflammation in the atherosclerotic plaque 
itself, or inflammation at another site, with secondary effects on the vascular wall. Molecular 
epidemiological studies designed to unravel the potential relationship between IL8 with CV 
and cancer mortality, as well as non-fatal MI should be of interest. In particular, further 
assessment of IL8 isoforms and anti-IL8 will be necessary to elucidate the behaviour of this 
chemokine in the spectrum of CVD.  
IL8 in serum did not differ among genetic variants at the IL8 and IL8R gene. One SNP at the 
promoter region of the IL8 gene was associated with a slightly increased risk of MI.  
However, it is important to realize that these results must be repeated in other 
epidemiological materials before robust conclusions are drawn.  A genetic variant coding the 
DARC gene was associated with IL8 in serum and, surprisingly, not with IL8 in plasma. 
Although initially confusing, these observations provide additional insight into the 
physiological and pathophysiological roles of this chemokine.  
Taken together, these results suggest that interpretation of circulating levels of IL8 in 
epidemiological studies should take into consideration the amount of IL8 internalized by the 
DARC, genetic predisposition, baseline characteristics of the population under study, time at 
which the blood sample is taken and whether the measurements are performed in serum or 
plasma. 
Elevation of the sIL6R and sgp130 had opposing associations with the occurrence of MI, and 
sgp130 was an effect modifier of the association between sIL6R with occurrence of MI. 
Furthermore, we observed an indication of a possible synergism between high sIL6R and low 
sgp130 with risk of MI. However, the lack of power to detect additive interaction requires 
further, larger studies. Future studies that will be of interest will be those aiming to replicate 
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these findings as well as to investigate whether the potential benefit observed with higher 
levels of sgp130 may be more substantial in a particular group of individuals. 
There may well be additional mechanisms at play which are beyond the scope of this thesis. 
Still, a number of crucial questions remain. First, can circulating levels of cytokines reflect 
the vascular state reliably enough to allow prediction of CVE? Indeed, to avoid misleadingly 
optimistic results, future studies are required to better assess the variability of biomarkers 
across time, as well as the impact of blood storage. Secondly, is the role played by IL8, sIL6R 
and sgp130 during the early and later stages of atherosclerosis similar? Thirdly, are the 
potential protective or deleterious effects of these biomarkers directly dependent upon their 
concentration? Answers to these questions may help elucidate the delicate risk-benefit 
balance and winding path involved in anti-inflammatory interventions. 
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10 SUMMARY IN SWEDISH 
Syftet med den här avhandlingen var att undersöka sambandet mellan inflammationsmarkörer 
och ischemisk hjärt-kärlsjukdom . 
Specifika syften var att studera sambandet mellan nivåer av IL8, såväl som genetiska 
varianter av IL8 och IL8 receptorer och hjärtinfarkt. Dessutom var syftet att undersöka om 
dessa genetiska varianter reglerar cirkulerande IL8-nivåer (Studie I); identifiera nya genetiska 
varianter associerade med cirkulerande IL8-nivåer (Studie II); studera sambandet mellan IL8 
nivåer och risken för kardiovaskulära händelser (Studie III) och slutligen att undersöka 
sambandet mellan nivåer av lösliga IL6 receptorer (sIL6R och sgp130) och förekomsten av 
hjärtinfarkt.   
Material och metod: Studie I, II och IV baserades på Stockholm Heart Epidemiology 
Program (SHEEP), en populationsbaserade fall-kontrollstudie. Fallen utgjordes av incidenta 
fall av hjärtinfarkt under perioden 1992 till 1994 som inträffade på 10 akutsjukhus i 
Stockholms län. Kontrollerna var slumpmässigt utvalda från studiebasen via density sampling 
och matchade för ålder, kön och sjukhusens upptagningsområden. I analyserna användes 
enbart fall av hjärtinfarkt utan dödlig utgång (n=1243) och matchade kontroller (n=1561) 
med tillgänglig data om biomarkörer. Exponeringsinformation insamlades via enkäter, 
medicinska register, blodprov och antropometriska mätningar. Studie III är en ”nested” fall-
kontrollstudie baserad på en kohort av 60-åriga män och kvinnor (60YO), som genomfördes 
mellan 1997 och 1999 i Stockholms län. Antal personer i studien var 4232. Fram till 31 
december 2012 har 491 hjärt-kärlhändelser registrerats.  För varje fall valdes könsmatchade 
kontroller (n=981) med liknande uppföljningstid. De var fortfarande under risk att insjukna 
(ej blivit fall under uppföljningsperioden), och ingick i kohorten 60 dagar före eller efter att 
den person som blivit fall inkluderats i kohorten.  
Resultat och slutsatser. I SHEEP var låga cirkulerande IL8-nivåer kopplade till förekomst av 
icke dödlig hjärtinfarkt (Studie I). I 60YO fanns inga samband mellan IL8 och risken för 
kardiovaskulära händelser (dödlig och icke dödlig hjärtinfarkt, dödlig och icke dödlig stroke 
och slutenvårdsbehandlad angina pectoris) (Studie III). IL8’s mediannivåer varierade inte 
med genetiska varianter av IL8 och IL8 receptorer. En SNP rs12075 A/G, Asp42Gly, som 
kodar för Duffy Antigen Receptor for Chemokines (DARC), visade på skillnader i nivåer 
beträffande IL8 i serum men inte i plasma. Lägre IL8-nivåer observerades hos personer med 
’’2 kopior’’ av G allele (homozygoter) (Studie II). Höga sIL6R-nivåer ökade risken för 
hjärtinfarkt. Sgp130 var en effektmodifierare av sambandet mellan sIL6R och hjärtinfarkt. 
Det fanns en indikation om en möjlig interaktion mellan höga sIL6R- och låga sgp130- nivåer 
och risken för hjärtinfarkt (Studie IV). Utifrån ett bredare perspektiv, borde betydelsen av 
molekylära signalvägar utvärderas i studier med målsättningen att kartlägga komplexa 
sjukdomar istället för att använda enskilda biomarköranalyser.  
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